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1. Abstract 
Background Acute bacterial meningitis (BM) continues to be an important cause of 
childhood mortality and morbidity, especially in developing countries. Prognostic 
scales and the identification of risk factors for adverse outcome both aid in assessing 
disease severity. New antimicrobial agents or adjunctive treatments - except for oral 
glycerol - have essentially failed to improve BM prognosis. A retrospective 
observational analysis found paracetamol beneficial in adult bacteraemic patients, 
and some experts recommend slow β-lactam infusion. We examined these 
treatments in a prospective, double-blind, placebo-controlled clinical trial. 
Patients and methods A retrospective analysis included 555 children treated for 
BM in 2004 in the infectious disease ward of the Paediatric Hospital of Luanda, 
Angola. Our prospective study randomised 723 children into four groups, to receive 
a combination of cefotaxime infusion or boluses every 6 hours for the first 24 hours 
and oral paracetamol or placebo for 48 hours. The primary endpoints were 1) death 
or severe neurological sequelae (SeNeSe), and 2) deafness.  
Results In the retrospective study, the mortality of children with blood transfusion 
was 23% (30 of 128) vs. without blood transfusion 39% (109 of 282; p=0.004). In 
the prospective study, 272 (38%) of the children died. Of those 451 surviving, 68 
(15%) showed SeNeSe, and 12% (45 of 374) were deaf. Whereas no difference 
between treatment groups was observable in primary endpoints, the early mortality 
in the infusion-paracetamol group was lower, with the difference (Fisher’s exact 
test) from the other groups at 24, 48, and 72 hours being significant (p=0.041, 
0.0005, and 0.005, respectively). Prognostic factors for adverse outcomes were 
impaired consciousness, dyspnoea, seizures, delayed presentation, and absence of 
electricity at home (Simple Luanda Scale, SLS); the Bayesian Luanda Scale (BLS) 
also included abnormally low or high blood glucose. 
Conclusions New studies concerning the possible beneficial effect of blood 
transfusion, and concerning longer treatment with cefotaxime infusion and oral 
paracetamol, and a study to validate our simple prognostic scales are warranted.  
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Resumo 
Introduҫão Meningite bacteriana aguda (MB) continua a ser uma causa importante 
da mortalidade e morbilidade infantil, especialmente nos países em via de 
desenvolvimento. Escalas de prognóstico e a identificaҫão de factores de risco de 
mau prognóstico ajudam a estimar a gravidade da doenҫa. Novos antibióticos ou 
tratamentos adjuntos, exepto o glicerol via oral, essencialmente falharam em 
melhorar o prognóstico da MB. Num estudo retrospectivo observador, paracetamol 
revelou-se benéfico nos adultos com bacteriemia, e alguns peritos recomendam 
infusão lenta de -lactam. Nós estudamos estes tratamentos num ensaio clínico 
prospectivo, duplo-cego, placebo-controlado.  
Pacientes e métodos A análise retrospectiva incluiu 555 crianҫas tratadas contra 
MB em 2004 na enfermaria de infecciologia do Hospital Pediátrico de Luanda, 
Angola. O nosso estudo prospectivo randomizou 723 crianҫas em quatro grupos, 
para receberem uma combinaҫão de infusão ou boluses de 6 em 6 horas de 
cefotaxima durante as primeiras 24 horas e paracetamol ou placebo via oral durante 
48 horas. Os eventos observados primários eram 1) mortalidade ou sequelas 
neurológicas severas (SeNeSe), e 2) surdez.  
Resultados No estudo retrospectivo, a mortalidade de crianҫas com transfusão de 
sangue foi 23% (30 de 128) e sem transfusão 39% (109 de 282; p=0.004). No estudo 
prospectivo, 272 (38%) crianҫas morreram. Das 451 sobreviventes, 68 (15%) 
apresentaram SeNeSe, e 12% (45 de 374) foram surdas. Embora não fosse 
observada nenhuma diferenҫa entre os grupos de tratamento nos eventos primários, 
a mortalidade inicial no grupo de infusão-paracetamol foi mais baixa, com uma 
diferenҫa significante (teste exacto de Fisher) dos outros grupos nas horas 24, 48 e 
72 (p=0.041, 0.0005, e 0.005, respectivamente). Factores prognósticos de mau 
prognóstico eram consciência alterada, dispneia, convulsões, atraso de comparência, 
e falta de electricidade em casa (Escala Simples de Luanda, ESL); a Escala 
Bayesiana de Luanda (EBL) incluiu também glicose no sangue baixa ou alta. 
Conclusões Novos estudos a respeito de possíveis efeitos benéficos de tranfusão de 
sangue e do tratamento mais longo com infusão de cefotaxima e paracetamol via 
oral, e um estudo para validaҫão das nossas escalas simples de prognóstico são 
justificados.  
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Yhteenveto 
Taustaa Äkillinen bakteerin aiheuttama aivokalvotulehdus (bakteerimeningiitti, 
BM) on yhä tärkeä lapsikuolleisuuden ja sairastavuuden syy, erityisesti 
kehitysmaissa. Prognostiset pisteytyssysteemit ja riskitekijöitten tunnistaminen 
auttavat taudin vakavuuden arvioimisessa. Uudet antibiootit tai liitännäishoidot, 
suun kautta annettavaa glyserolia lukuun ottamatta, eivät ole parantaneet BM:n 
ennustetta. Takautuva, havainnoiva tutkimus on osoittanut parasetamolin 
hyödylliseksi aikuisilla bakteremiapotilailla, ja jotkut asiantuntijat suosittelevat -
laktaamiantibioottien antoa hitaana infuusiota. Me tutkimme näitä hoitoja 
prospektiivisessa, plasebokontrolloidussa kaksoissokkotutkimuksessa. 
Potilaat ja menetelmät Retrospektiivisessa tutkimuksessa analysoitiin 555:n 
vuonna 2004 BM:iin sairastuneen lapsen hoitotuloksia Luandassa, Angolassa. Sen 
jälkeen toteutimme prospektiivisen tutkimuksen, jossa 723 lasta satunnaistettiin 
neljään eri hoitoryhmään, saamaan hidasta kefotaksiimi-infuusiota tai boluksia 
kuuden tunnin välein (ensimmäisten 24 tunnin ajan) yhdessä suun kautta annettavan 
parasetamolin tai plasebon kanssa (48 tunnin ajan). Hoidon päätetapahtumia olivat 
1) kuolema tai vakava neurologinen vammautuminen (VaNeVa) sekä 2) kuurous.  
Tulokset Retrospektiivisessä tutkimuksessa verensiirron saaneista lapsista kuoli 
23% (30/128) ja verensiirtoa saamattomista lapsista 39% (109/282; p=0.004). 
Prospektiivisessa tutkimuksessa 272 (38 %) lasta menehtyi. 451 eloonjääneestä 
68:lla (15 %) oli VaNeVa, ja 12 % (45/374) kuuroutui. Vaikka hoitoryhmien välillä 
ei lopulta ollut tilastollista eroa, infuusio-parasetamoli -ryhmän kuolevuus oli 
merkitsevästi pienempi (Fisherin tarkka testi) kuin muissa ryhmissä 24, 48 ja 72 
tunnin kohdalla (p-arvot 0.041, 0.0005 ja 0.005). Kehittämämme Yksinkertainen 
Luanda-skaala tunnisti alentuneen tajunnantason, hengitysvaikeudet, kouristukset, 
viiveen hoitoon tulossa ja kodin sähköttömyyden liittyvän huonoon ennusteeseen. 
Toinen pisteytysjärjestelmistämme, Bayesilainen Luanda-skaala identifioi yhden 
lisäennustetekijän: pienen tai suuren verenglukoosipitoisuuden.  
Johtopäätelmät Uudet tutkimukset verensiirron sekä pidemmän kefotaksiimi-
infuusion ja suun kautta annettavan parasetamolin mahdollisesta hyödystä sekä 
uusien prognostisten pisteytysskaalojemme validoimiseksi ovat aiheellisia. 
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3. Abbreviations 
 
AIDS  acquired immunodeficiency syndrome 
AUC   area under the curve 
BBB  blood-brain barrier 
BCS  Blantyre Coma Scale 
BERA  brain stem evoked response audiometry  
BLS  Bayesian Luanda Scale 
BM  bacterial meningitis 
Cbp A  choline binding protein A  
CI  confidence interval 
CNS  central nervous system 
COPD  chronic obstructive pulmonary disease 
COX  cyclooxygenase 
CRP  C-reactive protein 
CSF  cerebrospinal fluid 
CT  computed tomography 
dB  decibel 
DNA  deoxyribonucleic acid 
ECW  extracellular water 
GCS  Glasgow Coma Scale 
Hib  Haemophilus influenzae type b 
HIV  human immunodeficiency virus 
HTS  Herson-Todd Scale 
IL  interleukin  
IMCI   Integrated Management of Childhood Illness  
ISRCTN International Standard Randomised Controlled Trial Number Register 
iv  intravenous 
LP  lumbar puncture  
MBC   minimal bactericidal concentration  
MIC  minimal inhibitory concentration 
MRI   magnetic resonance imaging 
NMDA N-Methyl-D-aspartic acid 
OR  odds ratio 
PBP  penicillin-binding protein  
PCR  polymerase chain reaction 
PCT  procalcitonin  
SD  standard deviation 
SeNeSe  severe neurological sequelae  
SIADH  syndrome of inappropriate secretion of antidiuretic hormone  
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SLS  Simple Luanda Scale 
TEOE  transient evoked otoacoustic emissions  
TNF-α  tumor necrosis factor-α  
WBC  white blood cell count 
WFA  weight for age 
WHO  World Health Organization 
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4. Introduction 
Acute bacterial meningitis (BM) continues to be an important cause of child 
mortality globally, being responsible for 2% of all deaths in children younger than 5 
years.1 Still, survivors of BM have an about 20% risk of long-term disabling 
sequelae and impaired quality of life.2 BM is at least ten times as common in 
developing countries - where its mortality rates are much higher than in 
industrialized countries.3-6 Likewise, the risk of sequelae is highest in developing 
countries where disabled children can be subjected to stigma and neglect and hidden 
from view.2  
The introduction of Haemophilus influenzae type b (Hib), Streptococcus 
pneumoniae, and Neisseria meningitidis vaccines has changed the epidemiology of 
BM in industrialized countries. These vaccines are increasingly being applied 
throughout the world, but further efforts are needed, especially in developing 
countries.7  
Overall, child mortality has been declining worldwide, whereas the number of 
deaths caused by BM has decreased very slowly.8 Because new antibiotics have not 
improved the prognosis, research has focused on adjunctive medications. However, 
the benefit of dexamethasone is controversial.9, 10 Instead, glycerol has proved 
efficacious in reducing severe neurological sequelae (SeNeSe).11 Angola, a sub-
Saharan country with population of 18 million, has a high steady incidence and 
prevalence of BM.  In the Paediatric Hospital of Luanda, the capital, 50% of the 
5847 BM patients in 1998-2002 died.12 
Our retrospective study described the realities of BM in Luanda.  In our 
prospective, randomised clinical trial in the same hospital we aimed to find 
treatments to improve the prognosis of the disease.  
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5. Review of the Literature 
5.1 Definition, incidence, and epidemiology of 
childhood bacterial meningitis  
 
Bacterial meningitis is a bacterial infection which inflames the membranes that 
surround the brain and spinal cord. Although the frequency of acute BM in 
industrialized countries has declined, it continues to be a significant cause of 
childhood morbidity and mortality globally. In the United States, the overall 
incidence of BM is about 2 to 10 cases per 100,000 population per year. The 
incidence is greatest in neonates with about 400 per 100,000; this is followed by 
children younger than 3 years with 20 per 100,000, and is lowest in adults with 1 to 
2 per 100,000.13 In developing countries the incidence of meningitis in children is 
about 10 times as great as in industrialized countries.6, 8  
The aetiology of BM is affected most by the age of the child, but also by the 
geographical area where the child lives (Table 111, 12, 14-19). In the neonatal period, 
group B streptococci and coliform bacilli cause most BM in industrialized 
countries.20 In developing countries, in babies aged less than 1 week, E.coli and 
other Gram-negative bacteria such as the species Klebsiella, Enterobacter, and 
Salmonella, and in neonates older than 1 week, Streptococcus pneumoniae are the 
leading causes of meningitis.21-23 In infants and small children, before the 
introduction of Hib vaccination, H. influenzae, S. pneumoniae, and N. meningitidis 
were the leading agents. In children older than 5 years and in adolescents, S. 
pneumoniae and N. meningitidis are the predominant causes.20, 24 In developing 
countries, before Hib vaccination, S. pneumoniae seemed to be the leading causative 
agent of paediatric meningitis, followed by Hib, N. meningitidis, and Salmonella.25-
27  
In the Paediatric Hospital of Luanda, Angola, of the 246 bacterial agents 
identified in CSF samples from children aged 0-8 years with pyrexia and 
neurological signs, 82 (33%) were pneumococci, 68 (28%) H. influenzae, 50 (20%) 
meningococci, and 14 (6%) Salmonella spp.12 Meningococcal disease occurs 
sometimes as extensive epidemics, especially in the meningitis belt in sub-Saharan 
area.28, 29 Some Angolan provinces have also reported N. meningitidis epidemics.30 
In children with immunodeficiency or cerebrospinal fluid (CSF) shunt, various 
different bacteria, such as Staphylococcus species, Gram-negative enteric bacilli, or 
Pseudomonas aeruginosa can cause BM.31 
Factors that predispose the child to the development of infection at other 
sites predispose the child to the development of BM, as well. An increased 
incidence is observable in the very young; and boys are affected more frequently  
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than girls.8 Congenital or acquired abnormalities of the immune system, especially 
of the complement system, may predispose the child to BM.8, 32 Anatomical or 
functional asplenia increases the risk for meningitis by S. pneumoniae, H. influenzae 
or Gram-negative enteric bacteria. Children with malignant neoplasms with or 
without neutropenia, with systemic diseases, and with bacterial infections at other 
sites are also at increased risk.  Malnutrition also predisposes children to BM.8 
Neurosurgical procedures or cochlear implants, penetrating head injuries or CSF 
leaks increase the risk of BM, as well.24 
  
5.1.1 Epidemiology of Haemophilus influenzae meningitis 
H. influenzae type b meningitis affects mainly children aged 3 months to 3 years.20 
Before the advent of Hib vaccines, the incidence of H. influenzae meningitis varied 
worldwide. In Scandinavia the incidence was estimated to be 16 to 28 cases per 
100,000 children younger than age 5 years,33 but in non-industrialized populations 
like Alaskan Eskimos, Native Americans, Australian aboriginals, and African 
populations, the incidence was 3 to 10 times higher.8, 34 Before the introduction of 
conjugate vaccines, the incidence of Hib meningitis in the industrialized regions was 
estimated to be 32 cases per 100,000 children younger than 5 , causing 27,000 cases 
and 1,300 deaths per year; in developing regions the figures were 60 cases per 
100,000,  meaning 330,000 cases and 100,000 deaths annually.35 In another review, 
based on surveillance studies and laboratory-confirmed cases that are likely to 
underestimate the burden of the disease, the estimate for the incidence of Hib 
meningitis in children younger than 5 years in Europe in 2000 was 16, in Africa 46, 
and globally 31 per 100,000, causing a respective 5,200, 51,300, and 173,000 cases, 
which resulted in 2,000, 34,600, and 78,300 deaths (mortality 22–67%).4 Highly 
effective and safe conjugate Hib vaccines have almost eliminated Hib disease and 
meningitis in countries where they are routinely used.36-40  
The risk of spread of severe H. influenzae illness is increased especially in 
young household contacts, in day care centres, and in enclosed hospital 
populations.34 In the USA the incidence of H. influenzae meningitis used to be 
greater in blacks and in the rural white population, a fact  explained by poverty and 
lack of access to early medical care.8 The risk for invasive Hib infection in African 
people with sickle cell disease is 13-fold that of those without sickle cell disease.41 
  
5.1.2 Epidemiology of Streptococcus pneumoniae meningitis 
In a review of pneumococcal disease based on surveillance studies and laboratory-
confirmed cases—which are likely to underestimate the burden of the disease—the 
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estimate for incidence of pneumococcal meningitis in children younger than 5 years 
of age in Europe in 2000 was 6, in Africa 38, and globally 17 per 100,000, causing 
respectively 3,300, 43,100, and 103,000 cases, which resulted in 1,300, 31,700, and 
60,500 deaths (mortality 29-73%).5 In many countries where routine Hib vaccination 
has been implemented, S. pneumoniae has become the leading causative agent of 
BM.42 In a few countries with routine vaccination with 7-valent pneumococcal 
conjugate vaccine, a 56–69% reduction in childhood BM has been reported.43-45 
Pneumococcal meningitis generally occurs sporadically, but in recent years, 
countries located in the African meningitis belt have reported highly lethal 
epidemics.46-48 Similar to meningococcal meningitis, pneumococcal meningitis 
occurs there primarily in the dry season.49  
The risk of developing meningitis depends somewhat upon the serotype of 
the pneumococcus. Although >90 serotypes exist, meningitis is most commonly 
associated with serotypes 14, 6B, 19, 18C, 23, 4, 9V, 3, and 1.24, 34 In Africa, the 
most common serotypes are type 1, 5, and 6.6 The risk of pneumococcal meningitis 
is greater in indigenous people, in blacks, and is independent of income or 
population density.8, 50 Pneumococcal meningitis is 36 times greater in African 
people with sickle-cell disease than in those without sickle-cell disease.41 Moreover, 
HIV infection predisposes to invasive pneumococcal infection.51, 52 Children with 
cochlear implants have more than a 30-fold increased incidence of pneumococcal 
meningitis.53 The incidence of systemic infection with penicillin-resistant S. 
pneumoniae (MIC ≥2 μg/L) has been increasing since the 1960s. Resistance to 
third-generation cephalosporins has emerged more recently.8 Alterations in one or 
more penicillin-binding proteins (PBP) reduce their affinity for penicillin and other 
β-lactams, thus causing resistance. Several clones carrying altered PBP genes have 
spread in many parts of the world.54 
 
 
5.1.3 Epidemiology of Neisseria meningitidis meningitis 
Serogroups A, B, and C are responsible for most cases of meningococcal disease 
and meningitis globally, with serogroups B and C predominating in Europe and the 
Americas and serogroups A and C in Asia and Africa.55 In the USA the incidence of 
endemic meningococcal disease has been 0.9 to 1.5 cases per 100,000 per year. The 
rates are highest during infancy, adolescence, and early adulthood.56 In the African 
meningitis belt, from Ethiopia to Senegal, the incidence of endemic meningococcal 
disease is much higher. In addition, every 8 to 12 years occur outbreaks during 
which the rates can climb to 500 to 1000 cases per 100,000 population.55 The 
outbreaks occur during the hot and dry season; some suggest that the adverse 
climatic conditions damage local defences of the nasopharynx and thus predispose 
to the infection.6  
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The carriage rate for N. meningitidis in populations has been estimated to be 
between 1 and 15 percent. Carriers are usually school-age children and young 
adults. Higher carriage rates appear in lower socioeconomic classes,28 in patients´ 
household members, and kissing contacts.57 In most persons, carriage results in a 
systemic protective antibody response. Why, in a small number of carriers, N. 
meningitidis causes a systemic disease is unknown.55, 58  
The risk of acquisition of infection is increased in family members, in blacks, and 
in persons of low socioeconomic status, with exposure to tobacco smoke, or 
concurrent viral infection.55, 59, 60 New military recruits or college freshmen have a 
higher risk of sporadic and epidemic disease, which has been explained by crowded 
living conditions.55 In high school students, male gender, upper respiratory tract 
infection, marijuana use, and disco attendance associate with increased risk of 
meningococcal disease.61 Children with immunodeficiency or sickle cell disease are 
more susceptible to invasive meningococcal disease. Paediatric patients with 
meningococcal diseases should be screened for complement deficiency.8 HIV-
positive children are probably also at increased risk.55 
 
 
5.2 Pathogenesis and pathophysiology of childhood 
bacterial meningitis   
Bacteria enter the central nervous system (CNS) either by haematogenous spread or 
by direct extension from a contiguous site (Figure 154, 62, 63). In the neonatal period, 
bacteria are acquired mainly during birth from maternal genital secretions.24 In 
infants and children, the organisms that cause meningitis colonize the upper 
respiratory tract by attaching to the nasopharyngeal mucosal epithelium. All 
meningeal bacterial pathogens express various surface proteins that facilitate 
pathogen-host cell interaction. H. influenzae, S. pneumoniae, and N. meningitidis all 
produce immunoglobulin A proteases, which support colonization.13 Choline- 
binding protein A (Cbp A) and neuraminidase NanA are other pneumococcal 
proteins that aid the colonization of the nasopharynx.54 N. meningitidis uses fimbria 
or pili to adhere to the host´s mucosal epithelial cells.55 If the ciliated epithelial cells 
are damaged, as in viral infection or with smoking, their ability to prevent mucosal 
adhesion of invading bacteria is weakened.13   
S. pneumoniae uses Cbp A that binds to the polymeric immunoglobulin receptor 
to traverse the mucosal barrier.54 The bacteria traverse the endothelium by 
endocytosis (meningococci) or by separating tight junctions (H. influenzae) to 
invade intravascular space.13 Once in the bloodstream, encapsulated bacteria (eg. H. 
influenzae, S.pneumoniae, and N. meningitidis) avoid the host defence mechanisms, 
because their polysaccharide capsule inhibits neutrophil phagocytosis and 
complement-mediated bactericidal activity.13 The organisms then cross the 
vulnerable sites of the blood–brain barrier (BBB, e.g. cerebral capillaries and 
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choroid plexus) and reach the subarachnoid space.64 In the CSF, the organisms 
multiply rapidly because the host lacks defence mechanisms.62   
Meningitis can also develop by direct spread of bacteria from a paranasal sinus or 
from the middle ear through the mastoid process. Severe head trauma with a skull 
fracture or penetrating wounds can also lead to meningitis. Congenital dural defects 
such as dermal sinuses or meningomyelocele, or neurosurgical procedures can 
directly inoculate bacteria into the CSF.20  
When the pathogens have entered the CSF, they release active cell wall- or 
membrane-associated components; gram-positive bacteria liberate lipoteichoic acid 
and peptidoglygan, and gram-negative bacteria liberate lipopolysaccharide. β-lactam 
antibiotics that act on cell walls and cause rapid lysis of bacteria can in the 
beginning of the treatment cause a burst of release of these active bacterial 
products.65-70 The interaction of bacterial products with host pattern recognition 
receptors, such as Toll-like receptors, initiates the inflammatory reaction.71 As a 
consequence, CNS macrophages, astrocytes, ependymal, glial and endothelial cells 
release proinflammatory cytokines: interleukin (IL)-1β, IL-6, and tumour necrosis 
factor-α (TNF-α).24, 72 These cytokines stimulate chemotactic cytokines called 
chemokines (IL-8, macrophage inflammatory proteins), other chemotactic 
substances (complement factor C5a, platelet-activating factor), and adhesion 
molecules (intercellular adhesion molecule-1) which facilitate the passage of 
leukocytes from the circulation into the subarachnoid space.54, 72 Plasma and 
cerebrospinal concentrations of endotoxin and IL-1β, but not of IL-6 and TNFα, 
correlate with severity or adverse outcome of BM.8, 73-76  
Consequently, leukocytes release nitric oxide, toxic oxygen metabolites, matrix 
metalloproteinases, and prostaglandins, which results in injury to the vascular 
endothelium and alteration of the BBB permeability (Figure 154, 62, 63).  Penetration 
of low molecular-weight serum proteins into the CSF leads to vasogenic oedema. 
Bacteria and neutrophils release cytotoxic substances causing cytotoxic oedema. 
Increased CSF volume due to a blockade of CSF resorption across the inflamed 
arachnoid villi causes interstitial oedema. Cerebral oedema and intracranial 
hypertension contribute to neuronal damage. Cerebral blood flow increases early in 
meningitis, but decreases later, which can aggravate the neurological damage. In 
recent years research has focused on Toll-like receptors, reactive oxygen and 
nitrogen substances, excitatory aminoacids (glutamate, aspartate), matrix 
metalloproteinases, and caspases in mediating cellular apoptosis and neuronal 
death.20, 54, 63, 71, 72 
 
5.3 Clinical manifestations of childhood bacterial 
meningitis 
Bacterial meningitis can be insidious and develop progressively over one or several 
days. As it may be preceded by a nonspecific febrile illness, to define the exact 
21 
onset of meningitis is therefore difficult. Another pattern of the disease is acute and 
aggressive; the signs of sepsis and meningitis develop in a few hours.77  
 Meningitis is generally associated with nausea, vomiting, anorexia, irritability, 
headache, confusion, back pain, and nuchal rigidity (Figure 2). However, especially 
in young children, the symptoms and signs are often non-specific. The classic 
combination of manifestations: fever, neck stiffness, and altered mental status, is not 
always seen in infants. In infants, only irritability, restlessness, and poor feeding 
may be noticeable. Increased intracranial pressure may cause headache and 
vomiting in older children, and bulging fontanel and diastasis of sutures in infants.34  
In children and adults nuchal rigidity can associate with Kernig´s and Brudzinki´s 
signs. Kernig´s sign is positive when the leg is flexed 90 degrees at the hip and 
cannot be extended more than 135 degrees. Brudzinki´s sign is positive if the thighs 
and legs are flexed involuntarily when the neck is flexed.8 However, these signs are 
neither sensitive nor specific. In Kenya, only 40% of hospital-admitted children with 
neck stiffness had BM.78  
Petechial or purpuric lesions of the skin may accompany BM caused by any 
bacteria, but are more common in meningococcal meningitis. H. influenzae, S. 
pneumoniae, and N. meningitidis can attack joints, thus causing suppurative arthritis 
early, or reactive arthritis later during the disease.20 Facial cellulitis, 
endophthalmitis, pneumonia, and other suppurative manifestations can associate 
with bacteremia and meningitis.8   
In industrialized countries, seizures before or within 2 days of hospitalization 
occur in 20 to 30% of children with BM. Focal neurological signs, such as mono-, 
hemi-, or quadriparesis, facial palsy, ptosis (Figure 3), or strabismus, occur in about 
15% of patients with BM. Sometimes, ataxia or behavioural abnormalities are the 
presenting sign of meningitis. Subdural effusions, which are not generally 
associated with signs and symptoms and resolve spontaneously, can be 
Figure 2. Figure 3. 
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demonstrated in up to half of infants and children during acute illness. Rarely, a 
brain abscess appears as a complication of meningitis.8, 77  
Table 2 describes characteristics of children with BM in different geographical 
areas.11, 14, 15, 17, 19, 79, 80 In Africa, the diagnosis of BM is difficult partly because the 
clinical features overlap with those of malaria.25, 81, 82 At the initial clinical 
assessment, a diagnosis of meningitis is correctly included in only 30-40% of 
admissions for whom a final diagnosis of meningitis is recorded.25, 81, 83, 84 The 
Integrated Management of Childhood Illness (IMCI) guidelines advise primary care 
workers to refer all children with general danger signs or a stiff neck as potential 
meningitis cases.85, 86 In Gambia, a simplified set of IMCI signs (convulsions, 
lethargy, unconsciousness, or stiff neck) had a sensitivity of 98% and a specificity of 
72% to predict BM.87 However, in Kenya, 96% of children who met the IMCI 
referral criteria did not have meningitis. Their indicators for lumbar puncture (LP) 
or presumptive treatment were bulging fontanel, neck stiffness, cyanosis, impaired 
consciousness, partial seizures, and seizures outside the febrile convulsion age 
range, giving a sensitivity of 79% and specificity of 80%.88 Researchers from Papua 
New Guinea, also an area of malaria endemicity, recommend an LP in children with 
impaired consciousness, meningism, and multiple seizures, but not in a child with a 
single simple febrile seizure.89 Recent European guidelines agree with those 
preceding, but emphasize that some children with BM present with non-spesific 
signs which makes the diagnosis more difficult. 90, 91 
 
 
5.4 Diagnosis of childhood bacterial meningitis 
LP and examination of CSF are necessary for 
a definite diagnosis of BM. Physicians should 
always perform an LP immediately when 
they suspect the diagnosis (Figure 4). 
Sometimes LP is delayed or cancelled when 
concern about the risk of cerebral herniation 
has risen, in patients with papilloedema, focal 
neurological signs, impaired consciousness, 
immunocompromise, coagulation 
abnormalities, or cardiovascular instability.90, 
91 Abnormalities on computed tomography 
(CT) do not reliably predict cerebral 
herniation, and a normal CT does not exclude 
the risk of herniation; therefore, CT should 
not be used to decide whether it is safe to 
perform LP.90-92 CT plays a role in suspicion  
 
Figure 4. 
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of an underlying cause such as mastoiditis, and magnetic resonance imaging (MRI) 
in detecting and monitoring the complications of BM.93  
Analysis of CSF should include glucose and protein concentrations, white blood 
cell (WBC) count and differential, and Gram stain and cultures.20 Opening pressure 
is usually elevated; the average pressure is 300 mm H2O.8 The gross appearance of 
CSF is often used to determine the likelihood of BM. Turbid or cloudy CSF implies 
the presence of WBCs, red blood cells, bacteria, or protein. In BM, the leukocyte 
count is elevated, usually 1000-5000 cells/mm3, but can be <100 or >10,000 
cells/mm3. Usually neutrophils predominate, but about 10% of patients present with 
lymphocyte predominance. The CSF glucose concentration is <40 mg/dL (2.2 
mmol/L) in more than half of BM patients. A CSF to serum glucose ratio of ≤0.6 in 
neonates and ≤0.4 in older children is considered abnormal. Low CSF glucose 
concentration virtually excludes viral meningitis. In BM, the CSF protein 
concentration is elevated usually to 1,000 to 5,000 mg/L.8, 34, 94   
Where laboratory facilities are inadequate, urinary reagent strips have been tried 
as a means of low-cost CSF testing,95, 96 but in some studies their sensitivity has 
been low.97 In Kuwait, urine dipsticks identified all patients with normal CSF and 
97% of patients with abnormal CSF, and could distinguish viral from bacterial 
meningitis in 98%.98 By adding a test for nitrites, the sensitivity can be improved.99   
CSF culture is clearly the ideal, the "gold standard" for the diagnosis of BM,100 
but when antibiotics have been given, it lacks sensitivity (falls from 70-85% to 
below 50%20 ); and the culture facilities are expensive and difficult to maintain in 
developing countries. Pre-presentation antibiotics can alter other CSF parameters, as 
well: leukocyte counts can be reduced, lymphocytes predominate, and glucose 
concentrations rise.78, 101 As even oral antibiotics reduce CSF bacterial 
concentrations and yields of Gram stain and culture, parenteral antibiotics may 
sterilize CSF cultures within 1 hour for meningococcal meningitis and within 4 
hours for pneumococcal meningitis.102   
Gram staining of the CSF is 60-90% sensitive and 97% specific in diagnosis of 
BM. However, the likelihood of visualizing bacteria depends on the concentration of 
bacteria. Concentration techniques of the CSF, like centrifugation, enhance the 
probabilities of detecting bacteria.100, 103 Gram staining is positive in up to 15% of 
CSF that yield a negative culture result. Antibiotics before admission reduce the 
yield of Gram stain by 20%. Gram stain is rapid, inexpensive, and highly specific; it 
should direct initial therapy, especially where culture is unavailable.94, 101  
Several rapid bacterial-antigen detection tests have been developed to aid in the 
aetiologic diagnosis of BM. Latex agglutination is simple, does not require any 
special equipment, and gives results in 15 minutes, but requires a considerable 
amount of CSF, and the reagents are not cheap. Some authors have reported good 
sensitivity,104 increased sensitivity compared with culture in antibiotic-treated 
patients,105 and high specificity for the common meningeal pathogens. Its routine 
use has been questioned, but it might prove useful in patients pre-treated with 
antibiotics, or when Gram staining and culture results are negative or unavailable.94, 
101 The polymerase chain reaction (PCR) amplifies DNA from CSF of BM patients 
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to detect common meningeal pathogens.8 The results have been associated with high 
sensitivity, specificity, and predictive values. This method could prove useful in 
cases when Gram staining and culture remain negative. However, the method is 
expensive and rarely obtainable in developing countries.94 For study purposes, filter 
paper strips have proved an easy way to store CSF. The strips can be transported by 
regular mail to a centre with facilities for PCR.106    
Acute-phase reactants that have been used in the diagnosis of BM are not specific 
for BM. C-reactive protein (CRP) is useful in distinguishing bacterial from viral 
meningitis.107 CRP may help in cases in which CSF is suggestive of meningitis, but 
the Gram stain remains negative; normal CRP has a high negative predictive value 
in the diagnosis of BM.94 Procalcitonin (PCT) is also useful in distinguishing 
bacterial from viral meningitis; it increases in septic infection and decreases during 
antibiotic therapy rapidly.108, 109 It is, however, more expensive than CRP. In 
Malawian children, both CRP and PCT proved good predictors of serious bacterial 
infection, and BM; PCT had some value in predicting death, as well.110   
Complex predictive models have been developed in industrialized countries to 
distinguish between bacterial and viral meningitis. The Bacterial Meningitis Score 
has generally performed well but missed rare patients with BM.111 The Meningitest 
added procalcitonin and has showed 100% sensitivity and 52% specificity.112, 113  
Differential diagnosis of BM includes aseptic meningitis, brain abscess, epidural 
abscesses, bacterial endocarditis with embolism, subdural empyema, and brain 
tumours.8 Both BM and cerebral malaria cause fever, headache, and altered 
consciousness. In Kenya, 14% of comatose infants with positive malaria smear had 
proven BM; in sub-Saharan Africa even if malarial parasites are seen in the blood of 
comatose children, BM must be excluded.82 Partially treated BM is a diagnostic 
challenge in many developing countries where antibiotics can be bought freely over 
the counter. Differentiation between partially treated BM and tuberculous or viral 
meningitis is difficult with limited diagnostic resources. Viral aetiology (mostly 
enteroviruses) may account for 14-25% of all meningitis cases in Africa.101, 114 A 
rapid HIV test is important in areas of high prevalence. If the test is positive, 
Cryptococcus neoformans, Mycobacterium tuberculosis, and Toxoplasma gondii 
should be born in mind.101 In some areas of Africa, also trypanosomiasis, “sleeping 
sickness,” can cause meningoencephalitis.115 In some parts of Europe or North 
America, children with neuroborreliosis can present with subacute meningitis, facial 
or other cranial nerve palsies.116 
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5.5 Treatment of childhood bacterial meningitis 
5.5.1 Antimicrobials 
Factors in choosing an antimicrobial for BM are its activity against the probable 
pathogens and its ability to gain adequate bactericidal activity in CSF. Meningitis 
causes increased permeability of the BBB to most antibiotics. The concentrations of 
β-lactam antibiotics in CSF are 5 to 20% of respective serum values.24 Experimental 
models have shown that prompt bacterial killing in CSF is reached with antibiotic 
concentrations 4 to 5 times the minimum inhibitory concentration (MIC) of the 
specific pathogen.117  
The pharmacokinetic and dynamic properties of antimicrobials differ – and affect 
their bacteriologic efficacy. Aminoglycosides, fluorokinolones, and metronidazol 
are concentration-dependent agents; i.e. their effectiveness depends on the ratio 
between the peak concentration or area under the concentration curve of the 
antibiotic and the minimal bactericidal concentration (MBC) of the pathogen. β-
lactam antibiotics, aztreonam, and vancomycin exhibit time-dependent bactericidal 
activity; i.e. the time their plasma concentrations remain above the MIC determines 
their efficacy.118-120   
Traditional intermittent drug administration results in high peak and low trough 
serum levels and can result in concentrations below the MIC over a long period. 
Several animal studies suggest that it is efficacious to administer β-lactams 
continuously.121-124 In rabbits with group B streptococcal meningitis, cefotaxime 
infusion kills the bacteria effectively.125 The first reports of continuous antibiotic 
administration in humans included small numbers of patients,117, 126 until a meta-
analysis of randomised controlled trials suggested that continuous infusion of 
antibiotics is at least as efficacious as intermittent administration.127 In recent years, 
studies in critically ill patients have shown β-lactam infusion to equal an intermittent 
administration.128-130 In a randomised controlled study in COPD patients with 
respiratory tract infections, continuous cefotaxime administration led to greater 
proportions of concentrations >MIC and >5 x MIC compared with intermittent 
dosing.131 Some centres in Germany and Austria have since 1980s treated childhood 
pneumococcal meningitis with slow penicillin infusion.132  
The initial empiric antibiotics should cover the most likely pathogens for the age 
group of the patient. In neonates with early-acquired meningitis, the initial therapy 
is ampicillin with an aminoglycoside or cefotaxime. In late-onset neonatal infection, 
the therapy should cover staphylococci and include nafcillin or vancomycin, plus 
cefotaxime or ceftazidime. In infants of 1-3 months of age, ampicillin and a third-
generation cephalosporin (ceftriaxone or cefotaxime) is recommended, because of 
the probability of Listeria or enterococci in this age-group. After that age, 
monotherapy with a third-generation cephalosporin suffices.20, 133 However, in areas 
with pneumococcal resistance to penicillin and cephalosporins, addition of 
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vancomycin to the third-generation cephalosporin is a practice guideline. Moreover, 
in patients with basilar skull fracture the combination of vancomycin and third-
generation cephalosporin can be used. However, in patients with penetrating trauma, 
CSF shunt, or having had neurosurgery, the initial therapy should include 
vancomycin plus cefepime, ceftazidime, or meropenem.94, 134   
Treatment can be modified when the disease-causing pathogen is identified, and 
its antimicrobial susceptibilities are known. Penicillin G or ampicillin is still the 
standard therapy for susceptible (MIC ≤0.06 μg/mL) strains of S. pneumoniae or N. 
meningitidis; a third-generation cephalosporin is an alternative.135 A third-generation 
cephalosporin is indicated if the organism is not susceptible to penicillin (MIC ≥0.1 
μg/mL), but is susceptible to the cephalosporin (MIC ≤0.5 μg/mL). If the strain of S. 
pneumoniae is not susceptible to penicillin, and its MIC to the third-generation 
cephalosporin is ≥1.0 μg/mL, the patient should be treated with a combination of 
vancomycin and a third-generation cephalosporin. If the MIC to the third-generation 
cephalosporin exceeds 2 μg/mL, the addition of rifampin should be considered.50 
The standard therapy for β-lactamase-negative H. influenzae is ampicillin; a third-
generation cephalosporin is an alternative. If the strain produces β-lactamase, the 
therapy should be with a third-generation cephalosporin—chloramphenicol, 
fluoroquinolones, and meropenem being alternatives.94, 136  
WHO recommends the use of ceftriaxone as first-line therapy in Africa.137 This 
is, however, expensive, and therefore benzylpenicillin or ampicillin and 
chloramphenicol are still popular in many countries.101 A Cochrane meta-analysis 
found no significant difference in risk of death, deafness, or treatment failure 
between the third-generation cephalosporins and conventional antibiotics. The 
authors concluded, however, that the antimicrobial resistance has to be monitored.138 
Drug resistance is a major problem especially in developing countries, where 
facilities for culture and susceptibility testing lack and second-line antibiotics are 
too expensive.27, 101  
Duration of the antimicrobial treatment depends on the age of the patient, the 
causative bacteria, and the clinical course. In the past, when resistance was not a 
problem, BM was treated successfully with only one injection of long-acting 
sulfonamide,139 penicillin,140 or chloramphenicol, which was effective also against 
Hib and pneumococcus.141 Currently, for neonates with group B Streptococcus or 
Listeria monocytogenes, 10 to 14 days is recommended, and for Gram-negative 
enteric meningitis, a minimum of 3 weeks is necessary.24 In many parts of the world 
meningococcal meningitis is treated for 4 to 7 days; H. influenzae for 7 to 10 days; 
and S. pneumoniae for 10 to 14 days.24 However, a meta-analysis demonstrated no 
difference between short-course (4-7 days) and long-course (7-14 days) treatment 
with intravenous ceftriaxone regarding clinical success or long-term neurological or 
hearing sequelae.142  
In developing countries, the WHO recommends shorter courses.137 One 
intramuscular dose of ceftriaxone or oily chloramphenicol can effectively treat 
uncomplicated meningococcal meningitis.143 In meningitis caused by other bacteria, 
the WHO recommends 5 days of therapy for immunocompetent patients with 
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uncomplicated recovery. However, in immunocompromised patients, HIV patients, 
or in patients with persistent fever, seizures, and coma, therapy should be 
extended.101, 137 Salmonella meningitis requires at least 2 weeks of intravenous 
therapy.144  
The introduction of sulphonamides in the 1930s reduced mortality in bacterial 
meningitis from 98% to 25 %. The introduction of penicillin brought, however, only 
a modest decline in the mortality.145 Newer and more potent antimicrobial agents 
have failed to produce any further reductions in morbidity and mortality, except in 
cases caused by resistant bacteria.14 This unexpected outcome may result from the 
host´s inflammatory response to invading bacteria.54, 72 
 
5.5.2 Adjunctive Treatment 
Corticosteroids have been suggested as an adjunct to therapy of BM because they 
may reduce intracranial pressure 9 and modulate the production of cytokines.9, 70, 76, 
146, 147 Limiting dexamethasone therapy to 2 days seemed to be optimal.148 However, 
studies from developing countries have given differing results. In a prospective 
study in Pakistan, dexamethasone even proved harmful,149 and in Malawi no benefit 
was observable.19 A study in Latin America showed very little benefit even in Hib 
meningitis.11 Finally, in a recent meta-analysis (2010) of 2029 patients for which 
raw data were available, dexamethasone reduced any hearing loss among survivors 
of BM (OR 0.77, 0.60–0.99, p=0.04), but no significant effects occurred as to 
mortality or neurological sequelae, or in any subgroups (causative organisms, prior 
antibiotic treatment, HIV status, or age). The authors state that the benefit of 
adjunctive dexamethasone in BM remains unproven.10 In the latest Cochrane review 
(2010) of 4041 patients, dexamethasone reduced hearing loss and neurological 
sequelae in high-income countries. In low-income countries no beneficial effect 
appeared. Subgroup analysis of high-quality studies showed dexamethasone to be 
beneficial only in preventing severe hearing loss.150  
Glycerol (glycerine, 1, 2, 3-propanetriol), which is a naturally occurring trivalent 
alcohol, an essential compound of the human cell-membrane, an hyperosmolar 
agent and osmotic diuretic, was used for decades in neurosurgery and in 
neurological disorders, as well as in Ménière's disease.151-155 In one Finnish study, 
oral glycerol suggested a beneficial effect on neurologic sequelae of paediatric 
BM,156 and later a very large (n=654) study in Latin America clearly showed 
reduced risk of severe neurological sequelae of paediatric BM.11 The mechanism by 
which glycerol works is increase in serum osmolality and cerebral blood flow, and 
thus improved brain oxygenation. Osmotic diuresis plays a minor or no role.11, 157-159  
Non-steroidal anti-inflammatory drugs (NSAID) relieve the host´s inflammatory 
response.72 The inhibition of the cyclooxygenase (COX, prostaglandins, and 
thromboxans) pathway of arachidonic acid metabolism by NSAIDs (oxindanac, 
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indomethasin and diclofenac) has reduced inflammation in animal studies of 
meningitis.160, 161 In adults with clinical sepsis, ibuprofen reduced levels of 
prostacyclin and thromboxane and reduced fever, tachycardia, oxygen consumption, 
and lactic acidosis, but did not prevent shock or acute respiratory distress syndrome 
and did not improve survival.162, 163   
Some NSAIDs seem, however, to inhibit inflammatory reactions, also ones other 
than those mediated by inhibition of arachidonic acid metabolism, namely activation 
of neutrophils.164 Paracetamol (acetaminophen) is an inexpensive, effective, and safe 
antipyretic and analgesic drug much used in children.165-173 It has weak anti-
inflammatory activity and inhibits COX enzymes, especially COX3, and thus 
prostaglandin synthesis in the CNS, and NMDA (N-Methyl-D-aspartic acid) 
receptors in the hypothalamus.174-177 One observational study, a retrospective 
analysis of 809 adult patients with S. pneumoniae, S. aureus, E. coli, or P. 
aeruginosa bacteraemia in Helsinki, found paracetamol, in the final logistic 
regression analysis, to be independently associated with a reduced risk of death 
(odds ratio 0.24, 95% CI 0.11-0.51 and p value <0.001).178-180  
 
5.5.3 Supportive therapy 
Previously, fluid restriction has been the practise in BM to prevent the syndrome of 
inappropriate secretion of antidiuretic hormone (SIADH). SIADH causes 
hyponatraemia, which is common in BM, and is thought to worsen cerebral oedema 
and thus the outcome of BM.8 However, this viewpoint has been challenged.181-183 
Fluid restriction can result in decreased systemic blood pressure and impaired 
cerebral perfusion.184 Singhi and colleagues examined fluid restriction in BM 
children with or without hyponatraemia. Children with restricted fluids showed 
significant decreases in total body water and extracellular water (ECW). Children 
with ECW reduction of ≥10 ml/kg had higher mortality than children with <10 
ml/kg or no ECW reduction. Low plasma osmolality, low ECW at admission, and 
ECW reduction correlated with poor outcome.181   
A randomised trial in Papua New Guinea found fewer seizures after 72 hours, 
reduced spasticity at 14 days, and reduced neurological sequelae at 4 weeks in BM 
children with intravenous fluid at maintenance volumes vs. those with oral fluid 
restriction. Sunken eyes and reduced skin turgor associated with adverse outcome, 
especially in the fluid-restricted group.17 A recent meta-analysis preferred 
maintaining intravenous fluids rather than restricting them in the first 48 hours, in 
settings with high mortality rates and where patients present late. However, in 
industrialized countries, evidence was insufficient to guide practice.185 A recent 
European guideline recommends correction of dehydration with intravenous 
isotonic fluids, and fluid restriction only when evidence shows raised intracranial 
pressure or SIADH. 90, 91 In developing countries, nasogastric tube and enteral 
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hydration are used instead of intravenous fluids, which are more expensive and 
require skilled staff and more intensive supervision.101  
Possible hypovolaemia and shock should be checked for and if present, corrected 
urgently with isotonic intravenous fluids.17 In industrialized countries, vasoactive 
agents such as dopamine or dobutamine are infused to maintain normal blood 
pressure and to ensure sufficient cerebral circulation.8 Guidelines have been 
developed especially for treatment of meningococcal disease.90, 91, 186   
Simple measures such as attempts to reduce intracranial pressure include 30° bed 
head elevation and avoidance of head tilting and vigorous procedures. Control and 
prevention of seizures can be achieved with anticonvulsant medications: 
benzodiazepines, phenobarbital, and phenytoin.24 In Malawi, easy-to-use intranasal 
lorazepam was as effective and safe as intramuscular paraldehyde in children with 
protracted convulsions.187 In Ugandan children, buccal midazolam was as safe as— 
and in children without malaria also more effective than—rectal diazepam for the 
treatment of prolonged seizures.188 The high cost, however, of midazolam may 
prevent its use in developing countries. 
 
5.6 Prognosis and sequelae of childhood bacterial 
meningitis 
5.6.1 Prognosis  
The outcome of BM in developing countries is much worse than in industrialized 
countries (Table 311, 14, 15, 17, 19, 80). Mortality is approximately 5% in industrialized 
countries and 12-60% in resource-poor countries.3, 8, 15, 20, 26, 34 In 2000, Hib 
meningitis was estimated to have caused globally 78,300 deaths in children younger 
than 5 years, of which 34,000 were in Africa and 2,000 in Europe; the case fatality 
estimates were 43, 67, and 27%, respectively.4 The same estimates for 
pneumococcal meningitis were 60,500 deaths globally of which 31,700 were in 
Africa and 1,300 in Europe, case fatality estimates being 59, 73, and 38%, 
respectively.5 In a recent review of BM among African children, the reported in-
hospital mortality in pneumococcal, Hib, and meningococcal meningitis was 35, 25, 
and 4 %. Of children followed up after discharge, 10% died. 189   
Sequelae of BM include sensorineural hearing loss, decreased cognitive function, 
dizziness, seizures, motor deficits, focal neurological deficits, paralysis, blindness 
(Figure 5), and hydrocephalus.13 Less severe or minor sequelae documented are 
transient ataxia, behavioural problems, learning difficulties, unilateral hearing loss, 
hypotonia, and diplopia.2, 190   
Sequelae are reported in 15-20% of survivors of childhood BM in industrialized 
countries and in 25-50% in developing countries.3, 8, 26, 34 In a prospective study in  
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urban Senegal, the 66 survivors of 
BM had three times greater odds 
(65%) of major sequelae than did 
their 66 controls (41%); 52% had 
hearing, 40% cognitive, and 21% 
motor deficits, 21% seizures, and 
35% multiple impairments.191 In a 
recent meta-analysis (2010), the 
median risk of at least one major or 
minor sequela from BM was 20%. 
The risk of at least one major sequela 
(cognitive or motor deficit, bilateral 
hearing loss, visual impairment, and 
hydrocephalus) was 13%; 25% in 
pneumococcal, 10% in Hib, and 7% 
in meningococcal meningitis. In 
Africa, the risk of a major sequela 
was 25% vs. 9% in Europe.2  
Deafness is the most common 
serious complication of BM in 
children; deafness comprises one 
third of all major sequelae.2 In industrialized countries, approximately 6-14% of 
survivors are left with permanent sensorineural hearing loss.2, 3, 192-197 Hearing loss 
seems to develop during the acute stage of meningitis, but progression and 
fluctuation of hearing loss occur.193, 
198-200 The inner ear is the site of the 
auditory lesion.200, 201 S. pneumoniae 
causes hearing loss in 8-50%, H. 
influenzae in 3-40%, and N.  
meningitidis in 3-25% of the cases.2, 
197, 201, 202 Up to 25% of the children 
do not undergo any formal hearing 
test after BM, even in industrialized 
countries,192, 203 and the situation is 
much worse in developing 
countries.204 Brain stem-evoked 
response audiometry (BERA, ABR, 
BSA),196, 205 which measures the 
stimulus-evoked 
electrophysiological response of the 
VIIIth cranial nerve and brainstem, 
is useful in hearing assessment of 
childhood BM,206, 207 also in 
developing countries (Figure 6).208, 
Figure 5. 
Figure 6. 
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209 The transient evoked otoacoustic emission (TEOE) method is an alternative and 
cost-effective test for hearing screening. If TEOEs are absent, more precise methods 
should be used.210, 211  
Long-term consequences of childhood BM have gained attention in recent years. 
BM in children is associated with a substantial excess risk of intellectual, cognitive, 
and auditory impairment that persists into adolescence.212-216 In a review (2010) of 
1433 survivors of childhood BM, 49% had at least one long-term sequela; 45% 
behavioural or intellectual, 7% auditory, and 14% gross neurologic deficits.217 
 
5.6.2 Risk factors for unfavourable outcomes   
The prognosis of childhood BM varies depending on multiple clinical and 
laboratory factors (Table 4190, 218-222 ). Identification of these factors at hospital 
admission or during the course of the disease aids clinicians in finding the high-risk 
patients who are at greatest danger of dying or developing sequelae.  
Mortality is high in the neonatal period. Infections caused by Gram-negative 
enteric bacilli and pneumococci are, according to many studies, associated with 
higher mortality than those caused by H. influenzae or N. meningitidis..13, 20 Other 
factors associated with high mortality rates are decreased level of consciousness, 
signs of increased intracranial pressure, seizures, severe respiratory distress, need 
for mechanical ventilation, hypotension, delayed capillary filling, hyperthermia, 
malnutrition, delay in initiation of treatment, low CSF leukocyte count, low CSF 
glucose level, high CSF protein level, low white blood cell count, and low platelet 
count.13, 80, 221, 223, 224 In the USA, the death rates for H. influenzae meningitis used to 
be 3.5 times higher in blacks than in whites, which was explained by lack of access 
to early medical care.225, 226  
Impaired consciousness, seizures and prolonged seizures are signs of severe 
disease and their presence correlates with neurological sequelae. Risk factors are 
young age, hyperthermia, malnutrition, male gender, low blood and CSF leukocyte 
count, low CSF glucose, and high CSF bacterial load.80, 224, 227 The risk of hearing 
loss is increased with young age, impaired consciousness, seizures, ataxia, delay in 
treatment, previous antimicrobials, S. pneumoniae as the causative pathogen, 
absence of petechiae, low blood leukocyte count, low CSF glucose, and high CSF 
protein.193, 195, 202, 224, 228 Furthermore, low socioeconomic status associates with poor 
outcome.229, 230 Some studies have described higher risk of sequelae in indigenous 
than other populations.231, 232 
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5.6.3 Scoring systems for prognostication   
Scales based on risk factors can measure illness severity, assess therapeutic 
requirements and efficacy, and determine prognosis (Table 5222, 233, 234 ). They are 
valuable in studies and in comparisons between centres. Complex scales used in 
intensive care units in industrialized countries are not of much use in the developing 
world. 235-237  
Herson and Todd created a scale with nine clinical parameters (severe coma, 
hypothermia, seizures, shock, age <12 months, CSF leukocytes <1,000/mm3, 
haemoglobin <11 g/dL, CSF glucose <20 mg/dL, symptoms >3 days) at admission 
for predicting death or major sequelae after H. influenzae meningitis. Score >4 
indicates high risk.234 The scoring system is much used, and has proved useful in 
predicting major sequelae in other meningitides as well.232 A multivariate prognostic 
method based on likelihood ratios was created on the basis of initial clinical and 
laboratory data of Finnish children with BM.233 A Dutch scale identified male 
gender, atypical convulsions, low body temperature, and pneumococcal (and 
meningococcal) aetiology as independent predictors of death or neurological 
sequelae.238 Akpede and colleagues in Nigeria have developed a simple model for 
prognosis of an abnormal course (seizures during treatment) or adverse outcome 
(death or recovery with neurological sequelae) using six bedside features: age ≤2 
years, duration of illness >7 days, seizures, hypovolaemic shock, coma, and 
abnormal muscle tone.222  
As the status of consciousness seems to be the most important predictor of 
outcome in BM, coma scales are much used in prognosis, separately or as part of 
another scale.221, 239 The Glasgow Coma Scale (GCS) was developed to assess adults 
with cerebral trauma, and paediatric modifications soon followed.240, 241 The 
Blantyre Coma Scale (BCS), originally created to predict outcome in ≥1-year-old 
children with malaria is simple and easy to use, as it comprises only three clinical 
parameters: best motor response, best verbal response, and eye movements.242 
 
5.7 Prevention of childhood bacterial meningitis 
5.7.1 Vaccination 
Immunization is eventually the only effective method to prevent BM. Conjugated 
Hib vaccines have shown good protection in various studies,20, 243-245 including 
studies from developing countries.38, 40, 246, 247 Therefore, universal infant vaccination 
should be routine in all countries.136 However, 17% of the world´s countries do not 
have Hib vaccination in their national programme,7 and in many countries the 
coverage is not optimal.248  
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Pneumococcal conjugates combine 7 to 13 capsular serotypes in one vaccine.7 A 
decline in invasive pneumococcal disease and meningitis has been observable after 
the introduction of vaccine in many areas.43-45, 249 ,250, 251 Pneumococcal conjugate is 
recommended for children younger than 24 months, and for high-risk children 25 to 
60 months of age,50 but fewer than 50 countries have introduced pneumococcal 
vaccines into their programmes.7 International donors and the vaccine industry 
should negotiate affordable prices for poor countries.252 Serotype replacement has 
occurred in areas where 7-valent pneumococcal vaccines were introduced and 
necessitates surveillance to monitor vaccine impact and serotype distribution.7, 249, 
253 The first 7-valent conjugate did not include serotype 1, which in some areas of 
Africa causes almost half of all pneumococcal meningitis cases.47  
A quadrivalent meningococcal polysaccharide vaccine against serogroups A, C, 
Y, and W-135 is not recommended for children because of inconsistent 
immunogenicity at young ages. However, it is recommended for high-risk children 
older than 2 years, children with asplenia, HIV, or complement deficiency; for 
students living in dormitories, army recruits; for travellers to endemic areas, and 
during outbreaks.13, 20, 24, 254 A quadrivalent conjugate vaccine has been approved in 
Europe for adolescents over 10 years old, in the USA even for children over 2 years 
old.135, 255 To prevent epidemics of meningococcal meningitis in sub-Saharan Africa, 
the WHO recommends universal vaccination with group A meningococcal 
polysaccharide twice in infancy, followed by the four-valent vaccine in children 
older than 2 years.256 A group A meningococcal conjugate vaccine (MenAfriVacTM) 
has been shown to be safe and effective, especially in infants.257 Currently, there is 
no vaccine against group B meningococci licensed in industrialized countries. Great 
Britain and Canada have adopted universal vaccination with serogroup C conjugate 
vaccine.20, 24 
  
5.7.2 Chemoprophylaxis 
The risk for developing meningitis after exposure to a meningitis patient is much 
greater than in the general population, and chemoprophylaxis is indicated for high-
risk contacts.  Rifampin eradicates Hib from the pharynx in 95% of carriers 136 and 
reduces risk of secondary invasive illness in contacts (0/1112 in rifampin and 4/765 
in a placebo group, p=0.027).258 Chemoprophylaxis for H. influenzae meningitis is 
recommended for all household contacts, when at least one unvaccinated contact is 
younger than 4 years old; and for nursery or child-care contacts when at least two 
cases of invasive Hib disease have occurred within 60 days.136 Rifampin is the 
recommended agent. Index patients who do not receive third-generation 
cephalosporins or are younger than age 2 should receive chemoprophylaxis to 
eradicate Haemophilus colonization.136   
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For meningococcal meningitis, individuals considered high-risk are those who 
sleep or eat in the same household, and individuals who have had direct exposure to 
the patient´s secretions through shared utensils or toothbrushes, kissing, and school 
or day-care contacts in the prior 7 days. Health-care workers who have had direct 
mucosal contact with the patient´s secretions (mouth-to-mouth resuscitation) require 
chemoprophylaxis as well. Alternative medications are rifampin, ciprofloxacin, and 
ceftriaxone.13, 20, 24, 135, 245 Index patients who do not receive third-generation 
cephalosporins should receive chemoprophylaxis to eradicate nasopharyngeal 
carriage of meningococcus.135 For pneumococcal meningitis, no chemoprophylaxis 
is given.13, 24, 245 However, children with asplenia (anatomical or functional), 
regardless of their immunization status, should receive oral penicillin daily at least 
till 5 years of age to prevent pneumococcal infection.50 
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6. Aims of the Study 
6.1 General aim 
The aim of the study was, after gathering background data, to explore ways to 
improve the prognosis of childhood BM in a developing country.  
 
6.2 Specific aims 
1) To disclose the characteristics of childhood BM, its aetiology, outcomes, the 
sex and age distribution, and antibiotic resistance in Luanda in Angola, a 
sub-Saharan country [I]. 
2) To identify predictors of unfavourable outcomes in childhood BM in 
developing countries [II]. 
3) To assess the current knowledge about hearing loss in childhood meningitis, 
and to describe how hearing screening was established in Luanda [III]. 
4) To study whether the prognosis of childhood BM can be improved by 
instituting a β-lactam, such as cefotaxime, with a slow continuous infusion, 
instead of giving the same dose divided intermittently, and whether the 
prognosis would further be improved by high-dose oral paracetamol [IV].  
5) To compare the value of different prognostic scales in childhood BM [V]. 
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7. Patients and methods 
7.1 Patients 
The retrospective study included 555 children aged 0-12 years treated for BM in the 
infectious disease ward of Hospital Pediátrico David Bernardino, Luanda, Angola, 
in 2004 [I]. Of these children, 403 were analysed for the risk factors of death, 
whereas 249 children underwent an analysis of risk factors for severe neurological 
sequelae (SeNeSe) [II]. The prospective study enrolled and randomised 723 
consecutive children with suspected BM in a 36-month period of 2005-2008 [IV] in 
Hospital Pediátrico David Bernardino, Luanda, Angola [IV]. Of those 723 children, 
491 with confirmed BM and without an underlying condition were included in the 
analysis of prognostic scales [V]. 
 
7.2 Methods 
7.2.1 Study design 
The study was realized in Hospital Pediátrico David Bernardino which is a 
paediatric referral and teaching hospital in Luanda, the capital of Angola (Figure 7). 
The first two studies were retrospective analyses of children treated for BM during 
the calendar year 2004. The following three studies were prospective; the third was 
a descriptive study, the fourth a randomised clinical trial, and the fifth paper utilised 
data of the fourth study.  
 “Comissão de Ética do Hospital Pediátrico de Luanda” approved the prospective 
study on June 15, 2005, whereas the retrospective study did not require an official 
approval according to the local regulations. Children were included in the clinical 
trial only after their guardians’ informed consent. 
The prospective study was registered internationally as a randomised clinical trial 
(ISRCTN62824827). The children were randomised in blocks of 20 by use of a 
random number table, to one of the four groups: infusion of cefotaxime and oral 
paracetamol, infusion of cefotaxime and oral placebo, iv-bolus of cefotaxime and 
oral paracetamol, or iv-bolus of cefotaxime and oral placebo. 
In the retrospective study, BM was defined as confirmed if CSF culture, latex 
agglutination, or PCR were positive; or CSF leukocyte count (predominantly 
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polymorphs) was 
>50/mm3, and Gram stain 
positive. Meningitis was 
defined as probable when 
a child with symptoms 
and signs of BM had 
either CSF leukocyte 
count (predominantly 
polymorphs) >50/ mm3, 
or positive Gram stain. 
In the prospective 
study, BM was defined as 
confirmed when a child 
with compatible 
symptoms and signs had 
1) positive CSF culture, or 2) positive blood culture, or 3) positive PCR, or 4) at 
least two of the following criteria: CSF leukocytes ≥100/ mm3 (predominantly 
polymorphs), positive Gram stain, positive latex agglutination test, or serum CRP 
≥40 mg/L. 
 
 
7.2.2 Interventions in the prospective study 
When a child with probable BM arrived at the ward, a study nurse took from a box 
the next sealed envelope and administered the treatment as ordered by the card 
within. All children received cefotaxime 250 mg/kg/24 hours for 7 days. However, 
for the first 24 hours the children were randomised to receive cefotaxime as two 12-
hour infusions, or intermittently as four boluses every 6 hours.  
All children 
received both infusion 
and boluses, of 
cefotaxime and placebo 
(saline). If a child 
received cefotaxime as 
an infusion, saline was 
administered as boluses 
every 6 hours; if a child 
received cefotaxime as 
boluses, saline was 
administered as two 12-
hour infusions. As 
Figure 8. 
Figure 7. 
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ready-to-use cefotaxime is a yellowish liquid, black syringes and yellow iv-lines 
were used (Figure 8). 
As the trial used the two-by-two factorial design, the children were also 
randomised to receive paracetamol or placebo (water) orally for the first 48 hours. 
The solution made with paracetamol effervescent tablets resembles plain water. The 
first dose of paracetamol was 30 mg/kg, and the following doses 20 mg/kg every 6 
hours until the 48th hour. 
All children received glycerol 1.5 g/kg (1.5 ml/kg, maximum 25 ml) every 6 
hours for 48 hours. If the child had high fever or pain, ibuprofen was administered 
15 mg/kg, and repeatedly every 12 hours, if needed. Ringer´s fluid was used to 
correct hypovolemia. Normal maintenance fluids were administered intravenously, 
orally, or through a nasogastric tube. Anaemia, hypoglycaemia, seizures, and 
malaria were treated according to the guidelines of the hospital. 
  
7.2.3 Laboratory methods and follow-up 
The attending physician at the emergency department performed LP if there was any 
suspicion of BM, when a patient presented with impaired consciousness, seizures, 
meningismus, bulging fontanel or prostration. CSF samples underwent microscopy 
for leukocyte and erythrocyte count; glucose concentration was measured. Gram 
staining and bacterial culture were also performed. A latex agglutination test and 
susceptibility testing were done in Luanda, and real-time PCR for H. influenzae, S. 
pneumoniae, and N. meningitidis in the Instituto Nacional de Saúde, Lisbon, 
Portugal, resources permitting. 
When a child with BM was admitted, haemoglobin, blood glucose, malaria thick 
film, and CRP (prospective study) were examined immediately. Tests for full blood 
count, erythrocyte sedimentation rate, urea, HIV antibodies, sickle cell screening (if 
positive also electrophoresis of haemoglobin), urine analysis, tuberculin skin test 
with Mantoux technique, and 
(resources permitting) blood 
culture, were performed on the 
following working-day morning. 
Head ultrasound was carried out if 
a complication was suspected in an 
infant with a patent fontanel. 
Hearing was tested only in the 
prospective study. Transient 
evoked oto-acoustic emissions 
(Figure 9) and brain stem auditory 
evoked potentials were the 
techniques utilized immediately 
Figure 9. 
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after admission, and on day 7, and at the follow-up visits. In the prospective study, 
the physician of the infectious disease ward assessed the children daily during the 
hospital stay. On day 7, at discharge, and at the follow-up visits, a neurological 
examination was carried out. Special follow-up sheets were used. All children were 
called back for follow-up visits 1, 3, 6, 12, 18, 24, and 30 months after discharge. 
 
7.2.4 Outcome measures and statistical analysis 
In the prospective treatment study, the main outcome measures were 1) death in the 
ward or SeNeSe (blindness, quadriplegia/paresis, hydrocephalus requiring a shunt, 
or severe psychomotor retardation) and 2) deafness (better ear´s threshold >80 dB) 
at discharge. The secondary endpoint was death or any audiological (better ear´s 
threshold >40 dB) or neurological sequelae (in addition to SeNeSe; hemiparesis, 
monoparesis, any psychomotor retardation, or ataxia) [IV]. In the retrospective 
study, the main outcome measures were death in the ward or SeNeSe at discharge [I, 
II]. 
In the prospective study, at least 176 confirmed meningitis patients in the two 
main treatment arms each were required to detect a 15% decrease in the main 
outcome measures in favour of the infusion treatment, or of the paracetamol vs the 
placebo treatment by a two-tailed test with a power of 80%. To allow for a 5% error 
after adjustment for multiple testing (two endpoints and infusion vs. bolus, and 
paracetamol vs. placebo) we intended to enrol 750 patients. 
The data were analysed with StatView 5.1 (SAS Institute). Fisher´s exact test was 
used to test the statistical significance for comparison of nominal and an unpaired t-
test for continuous variables. The effect of blood transfusion on mortality was 
analysed also with logistic regression [I]. In the studies on risk factors [II, V] 
variables with a p value <0.1 in univariate analysis were submitted to a logistic 
regression model. 
In the prospective randomised trial, any possible interaction between the two 
main treatments of infusion and paracetamol was tested with two-way analysis of 
variance (ANOVA). The chi square test was used to test statistical significance of 
the differences in the primary and secondary outcomes for infusion vs. bolus, and 
paracetamol vs. placebo groups. Logistic regression modeling was applied to 
analyse the primary and secondary outcomes in the treatment groups, using the 
cefotaxime boluses–oral placebo group as the reference. The predefined subgroup 
analyses covered the aetiology and time of death. In the exploratory analysis of time 
of death, survival analysis, and Fisher’s exact and sign tests were used [IV].  
The Simple Luanda scale (SLS) was created by using five independent predictors 
of dismal outcome (death, SeNeSe, or deafness): electricity at home, days of illness, 
seizures on admission, consciousness, and dyspnoea. The Bayesian Luanda Scale 
(BLS) based on likelihood ratios equalled SLS, but took into account seizures at 
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home and added blood glucose concentration. To compare five scales we 
determined the best cut-off point, sensitivity, specificity, efficiency, and area under 
the curve (AUC) [V]. Posterior probability is the likelihood used in the Bayesian 
method [100 x likelihood ratio / (1 + likelihood ratio)]. 
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8. Results 
8.1 Acute childhood bacterial meningitis in Luanda 
(retrospective series) [I] 
Of the 555 children treated in 2004, 422 had confirmed and 60 probable BM. Of the 
412 meningitis cases with identified bacteria, 247 (60%) were caused by Hib, 98 
(24%) by pneumococcus, 42 (10%) by meningococcus, 18 (4%) by other 
streptococci, and 7 (2%) by other Gram-negative bacteria. Lowered sensitivity to 
penicillin and chloramphenicol, but not to third-generation cephalosporins was 
encountered. 
The median age of the children was 11 months; 9 with Hib, 11 with 
pneumococcal, and 30 months with meningococcal meningitis. Of the whole series, 
55% (283 of 510) were boys. Only 56% (165 of 294) of homes had electricity, and 
14% (40 of 296) running water, facts reflecting the low socioeconomic status of the 
family. Of 436 children, 139 (32%) were malnourished, shown by weight-for-age 
(WFA) less than -2 SD below the median. The children presented late; the median 
length of illness before admission was 7 days. Almost all children (337 of 410, or 
82%) had received some medication, 42% (131 of 313) had antibiotics before 
admission. 
Of 364 children, 106 (29%) presented in poor general condition. Only 39% (165 
of 424) were fully conscious. Seizures at home were reported in 65% (276 of 424) 
and were observed on admission in 34% (135 of 396). Focal neurological signs 
(fixed gaze, ptosis, facial paresis, hemiparesis) were reported in 23% (92 of 396). 
Dyspnoea was observed in 52% (205 of 398). Anaemia was very common, and 36% 
(113 of 312) of children had a haemoglobin level under 8 g/dL. Of the 9 children 
with confirmed sickle cell disease, 6 had pneumococcal, 2 Hib, and 1 S. pyogenes 
meningitis. 
Of the 213 children tested, 24 (11%) were HIV-positive. Among them, 8 had 
pneumococcal, 6 Hib, 1 Klebsiella pneumoniae, 1 meningococcal, 2 unidentified 
streptococcal meningitis; in 6 cases the agent remained unidentified. 
The most common antibiotic regimen (for 327 of 435, or 75%) was the 
combination of benzylpenicillin and chloramphenicol. However, ceftriaxone was 
instituted primarily, if Gram-negative bacilli were detected in microscopy. Malaria 
was treated in 55% (227 of 415), mostly with quinine. In all, 51% (204 of 399) 
required supplementary oxygen, and 54% (217 of 400), anticonvulsants. In the 
ward, still 20% (80 of 391) of children were dehydrated and needed rehydration 
which was generally accomplished with Ringer´s lactate.  
Blood transfusion, 15 ml/kg of packed red blood cells (tested for HIV, hepatitis 
B, and syphilis), was given to 31% (129 of 412) of children. It was executed when a 
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child showed haemoglobin <5 
g/dL, or if especially sick, <6 
g/dL. The children who received 
a transfusion presented more 
often in poor general condition or 
in coma, and were significantly 
younger. 
Mortality in the ward was 
35% (172 of 490); 38% from 
pneumococcal, 33% from Hib, 
12% fróm meningococcal, and 
54% from the other types of 
meningitis. Death took place on 
the third (median) day in 
hospital. The children who 
received a blood transfusion 
survived significantly better than 
the children who did not, their 
mortality being 23% (30 of 128) 
vs. 39% (109 of 282; p=0.003). 
In logistic regression analysis 
with other possible risk factors, the transfused children were at significantly lower 
risk of death (0.41, 95% CI 0.23-0.76, p=0.004). The beneficial effect of transfusion 
was maintained when the bacterial aetiology was included, or when those children 
who died during the first day were excluded from analysis. Of the children with 
confirmed or probable BM, 24% were left with severe (Figure 10) and 9% with 
moderate sequelae. 
 
8.2 Risk factors for death and severe neurological 
sequelae in childhood bacterial meningitis in 
Luanda [II] 
The main characteristics of the patients are described in Study I. Univariate analysis 
of the risk factors present at admission included 403 children and revealed the 
following predictors for death: seizures prior to admission, WFA <-2 SDs, poor 
general condition, impaired consciousness, low GCS, low BCS, seizures at hospital 
admission, presence of additional focus of infection, severe dyspnoea, and non-
meningococcal meningitis. In logistic regression analysis, only the following three 
were identified as independent risk factors for death: impaired consciousness (OR 
2.61, 95% CI 1.44-4.72, p=0.002), seizures during hospital admission (OR 2.49, 
95% CI 1.36-4.58, p=0.003), and severe dyspnoea (OR 2.42, 95% CI 1.17-5.03, 
p=0.02).  
Figure 10. 
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Univariate analysis of factors associating with SeNeSe included 249 children 
and revealed the following as predictors: delay in presentation, seizures prior to 
admission, WFA < -2 SDs, poor general condition, impaired consciousness, low 
GCS, low BCS, seizures at hospital admission, low CSF glucose level, and non-
meningococcal meningitis. In logistic regression analysis, only three remained as 
independent risk factors; convulsions during hospitalization (OR 9.34, 95% CI 3.49-
25.00, p<0.001), impaired consciousness (OR 2.96, 95% CI 1.32-6.63, p=0.009), 
and history of symptoms >3 days (OR 3.73, 95% CI 1.24-11.26, p=0.02). Treatment 
with ceftriaxone instead of the primary regimen of penicillin and chloramphenicol 
failed to improve outcome. 
 
 
8.3 Setting-up hearing screening in children with acute 
bacterial meningitis in Luanda [III] 
Of the 238 children with confirmed BM, 155 survived and of them, 131 (85%) had 
BERA tested. Of them, 34 (26%) had a hearing threshold ≥80 dB at discharge. A 
hearing deficit was associated with SeNeSe (p=0.002) and ataxia (p=0.009). 
 
8.4 Slow initial β-lactam infusion and paracetamol in 
childhood bacterial meningitis [IV] 
Of the 723 children enrolled in the study, 183 were randomised to receive 
cefotaxime infusion and oral paracetamol, 180 cefotaxime infusion and oral 
placebo, 180 cefotaxime bolus and oral paracetamol, and 180 cefotaxime bolus and 
oral placebo. All these children were analysed on an intention-to-treat basis. As 162 
children did not fulfil the criteria of BM, 34 had some exclusion criteria which were 
revealed only later in the ward, and 28 did not receive the complete study 
medication; 499 children were analysed per protocol. 
The causative bacteria were identified in 453 children (63%); being Hib in 188 
(41.5%), pneumococcus in 184 (40.5%), meningococcus in 49 (11%), and other, 
mostly Gram-negative bacteria in 32 (7%). No cefotaxime resistance was found. 
The median age of these children was 14 months (range 1-157 months), and of 
them, 386 (53%) were boys. Half the homes, 52% (379 of 722), had no electricity.  
The median length of illness before admission was 5 days (range 1-180), and 
63% (456 of 720) of patients had been ill for more than 3 days; 89% (636 of 718) 
had received some medication, 40% (271 of 679) antibiotics, 32% (230 of 723) had 
WFA < -2 SD. Seizures at home were reported in 70% (506 of 723) and observed on 
admission in 50% (360 of 722). Only 31% (224 of 723) of children were fully 
conscious; 24% (174 of 723) showed focal neurological signs, 25% (182/723) other 
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focus of infection, 16% (116/723) dehydration, and 46% (333 of 723) dyspnoea. 
Their median haemoglobin was 7.7 g/dL (2.3–15.6), and 88% had <10 g/dL. Median 
blood glucose was 119 mg/dL (18–506), 8% (60 of 715) had <40 mg/dL, and 48% 
(342 of 714) >120 mg/dL. 
In the ward, 38% (totalling 272) of children died. Of the survivors, 15% (68 of 
451) had developed SeNeSe and 53% (totalling 240)  some neurological sequelae at 
discharge; 83% (of 374) were tested for hearing, and of those children, 27% 
(totalling 96) could not detect the threshold of 40 dB, 12% (45 children), not even 
80 dB. With all the outcomes combined, 26% (102 of 392) had SeNeSe or deafness, 
68% (268 of 393) some neurological or hearing sequelae. Death or SeNeSe occurred 
in 47% (340 of 723) of the patients, death, SeNeSe or deafness in 56% (374 of 662), 
and death or any sequela in 80% (540 of 676).  
No significant differences in the treatment groups emerged in the primary or 
secondary outcomes: 1) death or SeNeSe, 2) deafness, or 3) death or any sequelae. 
However, in the subgroup analysis of pneumococcal meningitis, death or any 
sequelae occurred in 83% (73 of 88) among the infusion, but in 92% (81 of 88, 
p=0.07) of the bolus recipients. Among these children, infusion per se was 
beneficial, because risk of death or any sequelae was reduced in the cefotaxime 
infusion - oral placebo group when compared with the cefotaxime bolus - oral 
placebo group (OR 0.18, 95% CI 0.03-0.90, p=0.04). 
Although there was ultimately no difference in total mortality, the times of death 
differed. In the infusion group, mortality was lowered during the 4-48 hours from 
the institution of the treatment (54 of 363, or 15% vs. 80 of 360, or 22% in the bolus 
group, p=0.01). However, this change was transient, as after 48 hours the mortality 
was even higher in the infusion group (66, or 18% vs. 44, or 12%, p=0.03). In the 
paracetamol group mortality was lower 6-60 hours after the treatment initiation (53 
of 363, or 15% vs. 81 of 360, or 23% in the oral placebo group, p=0.006). The 
mortality in the cefotaxime infusion - oral paracetamol group was lower than in the 
other groups for 600 hours. When compared with the cefotaxime bolus - oral 
placebo group, the ORs were 0.45 (95% CI, 0.26 - 0.77; p=0·003) for 0-48 hours, 
and 0.52 (0.32 - 0.85; p=0·009) for 0–72 hours. When the cefotaxime infusion - oral 
paracetamol group was compared with all other groups, the difference (Fisher’s 
exact test) was most pronounced at 24, 48, and 72 hours, the p-values being 0.041 
and 0.0005, and 0.005, respectively.  
 
 
8.5 Prognostic accuracy of five scales in childhood 
bacterial meningitis [V] 
Of the 723 children in Study IV, 491 had confirmed BM and were without any 
underlying illness. They were analysed in the comparison of prognostic scales. Their 
characteristics were very similar to those of the entire series of 723 children. The 
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mean score on GCS, where optimal is 15, was 10.9 (SD 3.7). On BCS, where 
optimal is 5, the mean score was 3.4 (SD 1.4). On HTS, where 12 points is the worst 
grade, the mean was 4.1 (SD 1.9); 46% (219 of 474) of children were at high risk 
(score >4.0). 
On our new scales, for SLS—where the highest and worst score is 19—the mean 
score was 7.2 (SD 4.0). In the comparison of scales, we used a cut-off point of 8 or 
7. Regarding BLS, the likelihood ratio-derived posterior probability value (PR) for 
death was 46.5 (mean, SD 27.9); the cut-off point was 52. The mean PR for SeNeSe 
was 49.5 (SD 31.8) and the cut-off point 52. The mean PR for dismal outcome was 
51.2 (SD 30.6) and the cut-off point 45. 
The sensitivities of the SLS, BLS, GCS, BCS, and HTS for predicting dismal 
outcome were 76, 81, 81, 71, and 61%. The respective specificities were 68, 70, 67, 
74, and 69%. The scales predicted dismal outcome correctly in 72, 76, 74, 74, and 
65%. Of all scales, BLS proved to be the best predictor for dismal outcomes, 
because its AUC for death was 0.83, for death or SeNeSe 0.84, and for dismal 
outcome 0.82. SLS was not quite as accurate, but predicted death or SeNeSe well, 
its AUC being 0.82, and its specificity best of all (81%). Plain coma scales 
performed almost as well, HTS somewhat worse.  
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9. Discussion 
9.1 Prevention and diagnosis of acute childhood 
bacterial meningitis 
In the developing world, the incidence of meningitis is highest in African, mainly 
sub-Saharan countries.4, 5 Angola is a classical example.12   
It has been postulated that poverty and its consequences are responsible for the 
high incidence of BM in tropical Africa.6 In our study the children came from poor 
socio-economic situations, crowded homes having difficulties with sanitation. Many 
children were malnourished; WFA < -2 SDs was found in 32%, and many were 
anaemic. Several had sickle cell disease (screening test was positive in 36–32% in a 
retrospective–prospective study and in electrophoresis, haemoglobin SS was present 
in 41–67% of those tested) which raised the risk of invasive bacterial infections.41 
Of the children tested, 11–8% were HIV-positive. HIV leads to increased risk of 
pneumococcal meningitis, recurrent BM, and mortality from BM.52, 259 Some focus 
of infection other than meningitis was evident in 38–25% upon admission, and some 
children had developed meningitis as a complication of that infection (otitis or 
dental abscess). All these characteristics likely influenced the high incidence. 
In our retrospective study of 2004, 60% of cases were caused by Hib, 24% by 
pneumococcus, and 10% by meningococcus. In our prospective study from 2005 to 
2008, the corresponding figures were 42, 41, and 11%. Hib vaccinations were 
included in the national immunization programme at the end of 2006, and the 
numbers for Hib meningitis were declining. Developing countries have only a few 
vaccines in their national immunization programmes, because of economic 
constraints.7 Meningococcal vaccinations were rarely used in Angola when 
epidemics broke out.30 Pneumococcal conjugate vaccine would be highly welcomed, 
not only to prevent meningitis, but also pneumonia—an important killer in 
developing countries.5, 252 
However, even were the national programme comprehensive, vaccinations do not 
materialize in remote areas. They are administered in only some health centres or 
hospitals in large cities. Mobile campaigns are executed rarely, and mostly against 
polio, which campaigns are remunerated. 
In Luanda, the children with BM present very late in the disease, because the 
median length of time for symptoms before diagnosis is 7–5 days (retrospective – 
prospective study). Of these children, 82–89% had received some medication, 42–
40% antibiotics. The clinical picture of malaria with fever, convulsions, and 
impaired consciousness overlaps that of meningitis.81 Parents buy malaria and fever 
medications, or even antibiotics, in a pharmacy or market without a prescription. 
Many quack doctors or circulating nurses offer their unofficial services (Figure 11). 
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Traditional medicine and 
witchcraft still have strong roots in 
African societies.260 Even among 
the health care professionals, 
knowledge about BM is often 
poor.83  
Children in our series were very 
ill, with 29–53% (retrospective – 
prospective study) in poor general 
condition. At the emergency 
department, seizures were 
observed in 34–50%, altered 
consciousness in 61–69%, focal neurological signs in 23–24%, other focus of 
infection in 38–25%, dehydration in 13–16%, and dyspnoea in 52–46%. These 
findings clearly depict the realities in developing countries where most BM cases 
occur. In our retrospective study, among 717 patients, 123 (17%) died immediately 
after reaching the hospital, in the emergency department. In contrast, in our 
prospective study, where the transfer to the infectious disease ward was quicker, 
only 8 children died before reaching the ward. Obviously, many children arrived so 
late that they could not be helped. 
After the 27-year civil war ended in 2002, some development has taken place in 
Angola. The country has enormous natural resources which should be used for the 
benefit of her people to build up a functioning network of schools and health care 
facilities. Special emphasis should be put on preventive health care, education, and 
vaccination programmes. Educational work among parents and health care workers 
is needed to increase general awareness of BM (and other diseases) and to prevent 
delays in treatment. 
Indiscriminate use of antimicrobials reduces the chances of isolating the 
causative bacteria and leads to resistance problems. In our two studies, an agent was 
identified in 74 and 63% of cases. Much of the credit goes to a fruitful collaboration 
with the National Health Institute of Lisbon, which helped to establish the 
laboratory of bacteriology, the first in Angola, in the Paediatric Hospital of Luanda 
in 2002. It was soon obvious that bacterial resistance to inexpensive benzylpenicillin 
and chloramphenicol was common. However, in our retrospective study, ceftriaxone 
(started when Gram-negative rods were found) instead of penicillin-
chloramphenicol combination did not improve the prognosis – a finding which 
agrees with the Cochrane meta-analysis.138 No resistance against third-generation 
cephalosporins was encountered.  
 
Figure 11. 
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9.2 Treatment of childhood bacterial meningitis 
Despite expanding vaccination programs, BM continues to be among the leading 
causes of mortality from infectious diseases and is responsible for sequelae in 
survivors.1, 2 Therefore, better treatments should be sought. 
In Luanda, on arrival, 13–16% of children, but in the ward even more, 20–37%, 
were dehydrated. Dehydration should be corrected immediately, and in maintenance 
no fluid restriction should be executed.17, 182, 185   
In our retrospective study [1], the children receiving blood transfusions survived 
significantly better than did those without them (p=0.003). We have found no 
previous reports on this potentially important observation. The transfused children 
presented with a poorer status, obviously. The beneficial effect of transfusion is 
explained by better oxygen transport, increased blood volume, and likely better 
cerebral circulation. This finding deserves further investigation, although immediate 
blood transfusions in a tropical setting always pose their own problems. 
 
9.2.1 Slow initial β-lactam infusion and paracetamol    
Our prospective, double-blind, randomised clinical trial is the first to study the 
effects of β-lactam infusion and paracetamol in childhood BM. Even if the 
treatments failed to significantly affect the primary or secondary outcomes, some 
differences between the treatment groups emerged. In pneumococcal meningitis, 
which in many countries is currently the most common type of meningitis, the risk 
of death or any sequelae was reduced by cefotaxime infusion. The time of death 
differed between the groups: In the infusion group, mortality was lower for 4-48 
hours after the treatment initiation. Among the paracetamol recipients, mortality was 
lower for 6-60 hours. When the cefotaxime infusion - oral paracetamol group was 
compared with all other groups, the reduction in mortality was most pronounced at 
24, 48, and 72 hours (p-values 0.041 and 0.0005, and 0.005, respectively). These are 
findings that merit further investigation. 
 The explanation for the beneficial effects of continuous infusion is that high 
β-lactam concentrations of antibiotic are avoided, and rapid release of toxins and 
pro-inflammatory bacterial cell-wall products is prevented.69, 261 Importantly, 
continuous infusion has proved at least as effective and safe as traditional bolus 
administration in a number of studies conducted in animals and in patients.127, 262 In 
the present study, the initial beneficial effect of β-lactam infusion could probably be 
explained by prevention of bacterial multiplication or by slower killing of bacteria, 
and thus a lesser inflammatory storm. However, the beneficial effect was temporary, 
and one explanation for this is that the slow initial killing of bacteria could cause 
increased mortality later. 
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 In theory, NSAIDs could improve the outcome in BM or sepsis by reducing 
inflammation.72 However, in one randomised study, ibuprofen did not improve 
survival.163 Paracetamol, loosely considered as one of the NSAIDs, with its central 
inhibition of COX3 and NMDA receptors,175, 177 did, on the other hand, improve 
survival in a retrospective study on sepsis.178, 179 In our study, the beneficial effects 
of paracetamol were transitory. 
 In summary, cefotaxime infusion reduced death and all sequelae in 
pneumococcal meningitis. The combination of infusion and paracetamol reduced 
mortality during many days, although they were admnistered for only 24 and 48 
hours, respectively. Our view is that we ended our infusion + paracetamol regimen 
too early. 
 
9.3 Hearing tests in childhood bacterial meningitis 
BM is one of the most important causes of acquired sensorineural hearing loss in 
children.196 Hearing impairment after BM has been reported in up to half the 
survivors and is common in industrialized countries, as well.2, 192, 197 However, 
hearing screening is not a practice in many developing countries and not even for all 
BM children in the industrialized world.192, 203 Before our prospective study, 
measurements of hearing were not available in the Paediatric Hospital of Luanda. A 
child whose hearing impairment remains undiagnosed and therefore goes without 
any special support measures can be left in total isolation in society and without 
opportunities for the future. 
Comparison of the different study results is difficult, because their methods and 
auditory threshold levels vary. In many studies, hearing was tested only once with 
no follow-up. Because hearing loss in BM may be progressive or may resolve, 
repeated testing is recommended.200, 201 We showed that hearing screening is 
possible even in a developing country.  
We used brain-stem auditory evoked potentials and oto-acoustic emissions. The 
latter seemed to be very sensitive, as almost all children showed abnormal results. 
However, since it is quick and easy to perform, and the result is obtained 
immediately, perhaps it could serve as a screening test. The children who have 
absent otoacoustic emissions need the more complicated and time-consuming 
BERA which requires a specialist for interpretation. 
In summary, all children should undergo a hearing test after BM, and the test 
should be repeated, especially if the first test is abnormal. The testing should be 
done before hospital discharge so that all children would be tested, and should be 
repeated after a month to allow possible middle ear secretion to disappear. 
Researchers should all use the same standards, so that comparisons between studies 
are possible.  
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9.4 Outcomes of childhood bacterial meningitis in 
Luanda 
The outcomes of the children with BM in Luanda were miserable. Before our 
interventive study, half the children died. In our retrospective study of 2004 [I], the 
in-ward mortality was 35%, but if we add deaths in the emergency department 
(17%), no less than 46% of the children succumbed. In our prospective study [IV], 
the in-ward mortality was 38%, and almost no deaths occurred in the emergency 
department, thanks to the swift transfer to the ward.  
Neurological sequelae have not been defined in many studies, and if they have, 
the definitions have varied. Therefore, comparison of different studies is difficult. In 
our retrospective study [I], 24% of children with confirmed or probable BM were 
left with SeNeSe, 9% with moderate sequelae. In the prospective study (IV), 15% of 
children developed SeNeSe, which is notably less than in 2004. We believe that this 
is due to glycerol, which in a large study in South America reduced SeNeSe 
significantly,11 and which here was administered to all children. In 2004, 52% of 
children encountered death or SeNeSe; in 2005-2008, 47%. However, in 2004, less 
severe neurological sequelae such as ataxia went unreported. In our prospective 
study, 56% of children died or developed SeNeSe or deafness; 80% died or showed 
any sequelae. 
 We should aim for more extensive prevention and search for better 
treatments for this devastating disease. Studies should use comparable definitions 
for neurological sequelae.  
 
9.5 Prognostic and risk factors for unfavourable 
outcomes in childhood bacterial meningitis 
Identification of the risk factors on admission or during illness may provide 
clinicians with valuable information, because this helps to identify the patients at 
greatest risk. Thus—resources permitting—efforts could be maximized.  
Our finding of the association between delayed presentation and poor prognosis 
agrees with earlier findings from developing countries.221, 222, 224, 234 Lowered 
consciousness was the most important prognostic factor, as shown in other studies 
as well.221, 224 The risk of SeNeSe increased with prolonged unconsciousness, and 
convulsions were also a warning sign.220, 221, 224 In India, focal neurological signs 
(Figure 12) were associated with neurological sequelae.219 In our study this was the 
case only in univariate analysis, where, in addition, a concomitant focus of infection 
(mostly pneumonia) also correlated with poor outcome.263 Malnutrition, which in 
Latin America elevated the probability of death and of SeNeSe,80 showed this 
association here only in univariate analysis. However, 70% of children with severe 
malnutrition died. Unfortunately, slow capillary filling and low blood pressure, 
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found to be signs of poor 
prognosis,221, 224, 264 were not 
recorded in our retrospective study. 
In the prospective study, low blood 
pressure predicted death in 
univariate analysis, but in 
multivariate analysis showed only a 
trend towards it. Prevention and 
treatment of malnutrition, increased 
awareness of BM to aid in avoiding 
delay in presentation, and intensive 
treatment of convulsions and shock 
are among the measures to improve 
BM prognosis. 
Except for identification of the 
causative agent, laboratory analyses 
were, in our study, not very useful in 
predicting outcome. The risk of 
death and SeNeSe was reduced in 
meningococcal meningitis, and the 
risk of death increased in meningitides caused by other, mainly Gram-negative 
enteric bacteria. Low CSF glucose predicted SeNeSe, as in earlier studies,264 but 
only in univariate analysis. In the prospective study [V], low or high blood glucose 
associated with unfavourable outcomes. An association with low blood glucose was 
reported earlier,27 but, to our knowledge, an association with high blood glucose has 
been evident only in experimental pneumococcal meningitis.265 However, a link 
between hyperglycaemia and unfavourable outcome in sepsis and other severe 
disorders has gained attention in the past few years.266 Normal fasting blood glucose 
concentrations achieved with insulin treatment have improved the short-term 
outcome in a paediatric intensive care unit.267 Therefore, also meningitis patients 
require intensive blood glucose monitoring, and their hypoglycaemia should be 
corrected immediately. Hyperglycaemia should be avoided, and if necessary, treated 
with insulin infusions. 
 
 
9.6 Value of prognostic scales for unfavourable 
outcomes in childhood bacterial meningitis 
Our study is the first to compare the value of the Glasgow Coma Scale, Blantyre 
Coma Scale, and Herson-Todd Scale in bacterial meningitis. Based on our data, we 
created two new scales which showed the best predictive accuracy for all major 
outcomes. However, the Coma Scales were almost as accurate, which reflects the 
Figure 11. 
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importance of status of consciousness in this CNS disease. GCS is used worldwide, 
but inter-observer variations occur. BCS comprises fewer points, and is easier to 
use. 
HTS, which is probably the most common scale used in childhood BM, did not 
perform equally well. Our results agreed with the following risk factors of HTS: 
“severe coma, seizures, shock, and symptoms for more than 3 days”, but not with: 
“hypothermia, age <12 months, haemoglobin <11 g/dL, CSF leukocytes 
<1000/mm3, and CSF glucose <20 mg/dL”.234  
Some other scales have also been published,222, 233, 238 but have not been accepted 
into common use. The complex scales of the paediatric intensive care units in the 
industrialized world are of little use in developing countries. Interestingly, BLS, 
which included all the five parameters of SLS, but added blood glucose, did only a 
little better than SLS. It is quite surprising, how little laboratory results improved 
prognostic accuracy. Simple, easy to use, quick scoring systems are needed. We 
created two, but they must be validated in other populations, as well. 
 
9.7 Methodological aspects 
Our studies have some limitations. In our retrospective study [I, II] it was 
impossible to locate the hospital charts of the patients who died in the emergency 
department, and the children could not be analysed at all. Nor were the data 
complete from patients, especially if they had died soon after arrival. In 2004, 
hearing went untested; neither did we have any information on the follow-up visits.  
The prospective study [III, IV, V] had to exclude many children because of 
reasons unknown in industrialized countries; their parents were unaware of the 
treatment the child had received before admission. Some laboratory analyses such as 
HIV-antibodies, a sickle cell screening test, and a tuberculin test were performed 
only on the working day following admission. Patients who died quickly thus went 
untested. Because of problems with transport to Lisbon, Portugal, the PCR of the 
culture-negative CSF was done only in the beginning of our prospective study. Only 
one doctor, when present, performed head ultrasound examinations, only when there 
was suspicion of a complication. Some parents described the child´s condition 
fulfilling the exclusion criteria only after their inclusion in the study. Finally, some 
children received study medication dosage incompletely, some doses of oral 
medication being missed because of gastric retention or haemorrhage.  
Questions have risen as to the ethics of studies conducted by groups from 
industrialized countries in developing countries.268 Clearly, the clinical trials in 
developing countries should meet the same ethical standards as studies in 
industrialized countries, respecting the local conditions, customs, and culture. An 
ethics committee approved our study, and children were included only after 
informed consent was obtained. If the guardian was illiterate, a finger-print was 
acceptable. Our research addressed BM, which is an important health problem in 
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Angola, and tried to find simple and applicable solutions to improve its poor 
prognosis.  
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10. Summary and Conclusions 
Worldwide, acute BM still remains among the major causes of infection-related 
death and in survivors, causes permanent neurological disability. In developing 
countries, BM is ten times as common as in industrialized countries, and in 
resource-poor countries the risk of mortality and sequelae is much higher. As new 
antibiotics have not improved BM prognosis, aid has been sought from adjuvant 
medications. In earlier studies, dexamethasone has reduced hearing loss in 
industrialized countries, whereas glycerol reduces severe neurological sequelae. 
We launched a study in Angola where the burden of BM is grave and sought  
ways to improve its prognosis. The studies showed that children in Luanda have 
many additional diseases, such as anaemia, sickle-cell disease, and HIV infection, as 
well as malnutrition, all of which complicate their management. Most children 
present late in the disease, in a poor general condition with impaired consciousness 
and seizures. Public awareness of the symptoms and signs of BM should be 
promoted, and health care workers trained in the diagnosis of BM to prevent delays 
in treatment.  
Early prediction of a poor outcome can help the physician to determine which 
children require more intensive management and follow-up. We identified the most 
important prognostic factors for adverse outcomes: absence of electricity at home, 
delay in presentation, impaired consciousness, seizures, dyspnoea, and low or high 
blood glucose concentration. Our two new prognostic scales: the Bayesian Luanda 
Scale (BLS), and Simple Luanda Scale (SLS), performed better than the Glasgow or 
Blantyre Coma Scales. The Herson-Todd Scale proved the weakest of all these 
scales. The level of consciousness was the most important prognostic factor and by 
adding some clinical parameters and (where possible) one laboratory test (blood 
glucose), we delivered a scale which predicted the outcome of BM quite reliably. 
However, our scales require validation in other populations. 
Many children were dehydrated on admission, and even more children in the 
ward. In the treatment, emphasis should be put on fluid management: correction of 
dehydration and normal, not restricted, maintenance fluids. The finding of reduced 
mortality in blood transfusion recipients deserves another study.  Low or high blood 
glucose was associated with unfavourable outcomes. Meningitis patients require 
intensive blood glucose monitoring. Hypoglycaemia should be corrected 
immediately, and hyperglycaemic BM patients may benefit from insulin infusions. 
In our trial, no specific treatment alternative (none of the combinations: infusion or 
bolus plus paracetamol or placebo) finally affected the primary or secondary 
outcomes, but initial mortality in the infusion – paracetamol group fell more than in 
any other study since the advent of chloramphenicol and ampicillin some 50 years 
ago. In pneumococcal meningitis, the risk of death or any sequelae was reduced in 
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children who received cefotaxime infusion. We are planning a new study with 
longer treatment periods. 
After Hib vaccinations began in Angola in 2006, the numbers of Hib meningitis 
cases have rapidly decreased. Improving the coverage of Hib vaccination and the 
introduction of pneumococcal and meningococcal vaccinations pose a major 
challenge to the health authorities; also much political will and good funding are 
required. While awaiting these, better treatments for BM should be sought. 
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Kiitokset 
Kiitän kaikkia niitä Angolan lapsia ja heidän vanhempiaan, jotka ovat olleet mukana 
tässä tutkimuksessa. Heidän ansiostaan tutkimus oli mahdollinen. 
Olen kiitollinen tohtori Luis Bernardinolle, Luandan lastensairaalan 
johtajalle, lämpimästä vastaanotosta ja kaikesta tuesta tutkimuksen aikana. Kiitän 
kaikkia Luandan lastensairaalan kollegoita, erityisesti Joaquina Magalhãesia, Ana 
Paulaa, Maria Ódia de Sousa e Silvaa, Margarida Correiaa ja Manuel Leite 
Cruzeiroa korvaamattomasta avusta tutkimuksen käytännön suorittamisessa, samoin 
kiitän laboratoriohenkilökuntaa: Elizabete dos Anjosta, Marlene Pardalia, Joaquina 
Madalenoa ja Afonso Sozinhoa likvornäytteiden keräämisestä ja tutkimisesta. 
Portugalilaiset kollegat Lurdes Monteiro, Maria João Simões, Catarina Freitas, Ana 
Pelerito ja Laura Brum ovat angolalaisten kollegoiden kanssa tehneet suurenmoisen 
työn pystyttäessään Luandan lastensairaalaan mikrobiologisen laboratorion, jota 
ilman tämä tutkimus ei olisi voinut toteutua. Kiitän lasten infektio-osaston 
osastonhoitajaa Julieta Alfredoa ja apulaisosastonhoitaja Dona Fátimaa sekä 
tutkimushoitajiamme Ana Paula Monteiro de Castroa, Domingas Bernardo da 
Costaa, Eduarda Maria Combo Kutia, Filipa Camposta, João Luindulaa, Maria 
Filomena Soares da Costaa ja Noé Manuel Lemosta, jotka uurastivat pitkiä päiviä 
hoitaen vakavasti sairaita lapsipotilaitamme.  
Olen syvästi kiitollinen professori Heikki Peltolalle, tutkimuksen 
alkuunpanijalle ja “priimusmoottorille”, innostavasta ohjauksesta sekä monista 
arvokkaista kommenteista kirjoitustyön aikana. Kiitän Irmeli Roinetta 
kärsivällisestä opastuksesta monissa tutkimustyön käytännön asioissa, Matti Katajaa 
tilastotieteeseen perehdyttämisestä, professori Anne Pitkärantaa rohkaisusta ja 
käytännön vinkeistä varsinkin väitöskirjatyön loppuvaiheissa sekä Carol Norrisia 
kielentarkastuksesta ja englanninkielen saloihin perehdyttämisestä. Haluan kiittää 
dosentti Marjo Renkoa ja professori Jussi Mertsolaa väitöskirjatyön nopeasta ja 
asiantuntevasta tarkastuksesta sekä rakentavista korjausehdotuksista. 
Lausun kiitokseni Suomen Lähetysseuralle mahdollisuudesta tehdä 
Angolassa osa-aikatyötä, jota ilman tutkimus olisi ollut mahdoton. Pastori Maija 
Kuoppala tuki ajatusta tehdä samanaikaisesti kirkon työtä ja tutkimustyötä. Kiitän 
Angolan evankelisluterilaisen kirkon johtoa sekä sen terveydenhuolto- ja Aids-työn 
kollegoita, ystäviä, jotka myös ymmärsivät “jakautuneen työnkuvani”. Kiitän 
Helena Åströmiä ja muita Lähetysseuran entisiä ja nykyisiä työtovereita 
ystävyydestä ja tuesta sekä monenlaisesta käytännön avusta Angolan vuosien 
aikana. Monet ystävät ja esirukoilijat nimikkoseurakunnissa sekä “Angolan 
rukouspiirissä” ansaitsevat lämpimät kiitokset. Olen kiitollisuudenvelassa 
Sveitsiläiselle lähetykselle ja Christa Bezille, joka antoi minulle majapaikan 
kotonaan Luandassa. Kiitän Lähetysseuran kollega-esikoulutusharjoittelijoita, 
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erityisesti Anni ja Marko Taipaletta, jotka osallistuivat tutkimustyöhön ja Siiri-
tyttärensä kanssa toivat myös paljon iloa Luandan suurkaupunkielämän keskelle. 
Haluan kiittää HYKS:n lastenklinikan lääkäreitä ystävällisyydestä ja 
kärsivällisyydestä, kun ovat opastaneet Afrikasta tullutta kollegaa uudestaan 
länsimaisen lääketieteen “tavoille”. Kiitän lasten infektiopoliklinikan ja -osaston 
kollegoita, erityisesti dosentti Eeva Saloa ja dosentti Harri Saxenia, sekä hoitajia ja 
kaikkea henkilökuntaa ystävyydestä ja hyvästä työyhteydestä. Olen 
kiitollisuudenvelassa ystävilleni, dosentti Leena Vainionpäälle rohkaisusta 
tutkijantiellä ja sukulaiskollegalleni Tuula Tervolle jaetusta Angola-innostuksesta. 
Kiitän HYKS:n syöpätautien ja naistentautien klinikan sekä Töölön sairaalan 
henkilökuntaa saamastani hyvästä hoidosta. 
Kiitän Suomen Lähetysseuraa, Sigrid Juseliuksen sekä Päivikki ja Sakari 
Sohlbergin säätiöitä, Lastentautien Tutkimussäätiötä sekä “Helsingin Sanomat” – 
sanomalehteä tutkimuksen taloudellisesta tukemisesta. 
Omistan tämän kirjan perheelleni, vanhemmilleni Irja ja Hannu Pelkoselle 
sekä sisaruksilleni Ulla Mäkiselle, Heikki, Sauli ja Mikko Pelkoselle perheineen. 
Olen syvästi kiitollinen kaikesta heidän rohkaisustaan, tuestaan ja rakkaudestaan, 
johon olen aina voinut luottaa. 
Lopuksi kiitos Taivaalliselle Isälle, elämän antajalle ja ylläpitäjälle.  
“Mikä voi meidät erottaa Kristuksen rakkaudesta? Olen varma siitä, ettei 
kuolema eikä elämä, eivät enkelit, eivät henkivallat, ei mikään nykyinen eikä 
mikään tuleva eivätkä mitkään voimat, ei korkeus eikä syvyys, ei mikään luotu voi 
erottaa meitä Jumalan rakkaudesta, joka on tullut ilmi Kristuksessa Jeesuksessa, 
meidän Herrassamme.” Room.8:35, 38-39 
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